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Abstract 
Core binding factors are heterodimeric transcription factors composed of 
two subunits, alpha and beta. In mammals, the alpha subunit is encoded by three 
genes, AML1, 2, 3 (also known as RUNX1, 2,3), whereas only one gene encodes the 
beta subunit CBFB. AML1 and CBFB have a pivotal role during embryonic 
haematopoiesis as both Aml1 and Cbfb Knock-out mice lacked definitive 
haematopoiesis and died at 12.5 dpc. In addition, these two genes are the most 
frequent targets for chromosomal translocations in leukaemia generating AML1-
ETO (AE) fusion and CBFB-SMMHC fusion, respectively. Although, Cbfb enhances 
the binding affinity of AML1 to DNA, its role in AE-mediated transformation remains 
unclear. Recent studies by others and our group using Cbfb-interaction defective AE 
mutants in different experimental settings have yielded conflicting results (Kwok, 
Zeisig et al. 2009; Roudaia, Cheney et al. 2009). Definition of Cbfb requirement is 
important for understanding the biology of the disease and also for designing 
better cancer therapeutics. 
Thus in my PhD project, we aim to clearly define the role of Cbfb in AE-
mediated leukaemogenesis and also to investigate the effect of Cbfb deletion on 
the development of HSCs. To achieve the proposed aims, we used Cbfb conditional 
knockout mouse model (Cbfbfl/fl Rosa 26 Cre ER) where only an alternatively 
spliced form of Cbfb that is incapable of interacting with AE will be expressed. Our 
in vitro data showed that deletion of Cbfb resulted in a reduction of the 3rd round 
colonies, but does not completely impair AE-mediated transformation of the 
primary mouse hematopoietic cells. In addition, the Cbfb-interaction defective AE 
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mutant Y113A/T161A was able to transform all the sorted distinct haematopoietic 
cell populations including LSK stem cell-enriched populations, common myeloid 
progenitors (CMP) and granulocyte and myeloid progenitors (GMP). To investigate 
the role of Cbfb in leukaemogenesis, I employed an AML mouse model generated 
by expression of AML1-ETO9a (AE9a) into fetal liver cells.  In contrast to MN1-
mediated leukaemogenesis, Cbfb was crucial for both the leukaemia development 
as well as its maintenance.  To study the role of Cbfb in normal haematopoiesis, we 
conditionally deleted Cbfb at the adult stage and analysed its impact on normal 
haematopoietic development. Our data showed when Cbfb was ablated in the 
whole animal or only in the haematopoietic system, haematopoietic 
stem/progenitor populations were significantly compromised. In addition, Cbfb KO 
cells were incapable of reconstituting secondary recipient mice. Strikingly, no 
haematopoietic defect was observed when Cbfb was ablated only from the 
microenvironment. The data showed an important function of Cbfb in maintaining 
normal haematopoiesis in a cell-autonomous manner. Together, these results 
reveal an important function of Cbfb in both normal and malignant haematopoiesis. 
On-going effort on RNA/ChIP-sequencing and future functional validation of 
candidate downstream targets will further shed light into the underlying 
mechanisms for the function of Cbfb, and development of novel therapeutic 
strategies for AE9a leukaemia and HSC transplant.  
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 Chapter 1 Introduction  





Stem cells are distinguished from other cells in having the unique ability to 
maintain long-term self-renewal, and also to differentiate into multiple cell types 
(Metcalf 2007). These cells can be broadly classified into two main categories: 
embryonic stem cell, and adult or tissue specific stem cells. Establishment and 
maintenance of the haematopoietic system relies on adult stem cells called 
haematopoietic stem cells (HSCs). In fact, the haematopoietic system is probably 
one of the most highly regenerative tissues as around 1012 cells are generated daily 
in the adult human bone marrow (BM). Despite the complexity of haematopoiesis, 
it is considered as one of the best understood developmental system. In 1909, 
Alexander Maximow postulated that blood is organized as a cellular hierarchy with 
a single cells at its apex looking like a lymphocyte (Doulatov, Notta et al. 2012). Four 
decades later, this hypothesis was proven by an functional rescue experiment 
where the haematopoietic system was completely reconstituted in irradiated mice 
by transplantation of cells isolated from healthy donors (Lorenz, Uphoff et al. 1951). 
However, this experiment did not distinguish if the haematopoiesis is arising from a 
single stem cell or from different lineage specific stem cells. Till and colleagues were 
able to demonstrate the clonal nature of spleen colonies that derived from 
transplanted mouse BM. The data showed that when a single colony carries a 
recognizable chromosomal marker, majority of the cells carry the same marker 
suggesting the existence of multipotent HSCs (Till and Mc 1961; Becker, Mc et al. 
1963). In general, the production of blood can be divided into two main stages: 
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embryonic and adult haematopoiesis in which different embryonic and adult organs 
play crucial roles to maintain and regulate this process. 
1.1.1 Embryonic haematopoiesis  
 
In mammals, the initial wave of blood cell production takes place in the yolk 
sac, which generates transitory haematopoietic cells such as primitive erythrocytes 
and some myeloid cells. This type of blood formation is called primitive 
haematopoiesis and its main function is to facilitate tissue oxygenation of the 
growing embryo (Orkin and Zon 2008; Medvinsky, Rybtsov et al. 2011). During 
mouse embryonic development, primitive haematopoiesis occurs between day E7 
and E7.5 in the yolk sac, and by day E9.5 Aorta-Gonad-Mesonephros (AGM) has 
higher numbers of CFU-S than the yolk sac (Medvinsky, Samoylina et al. 1993). 
Although by E8 the heart starts beating, massive movement of the yolk sac 
erythroid cells into the embryo’s body is observed only at E10 due to lack of a 
complete development of primitive vascular system (McGrath, Koniski et al. 2003). 
The second wave of blood formation is called definitive haematopoiesis, in which 
definitive haematopoietic stem cells (dHSCs) give rise to all mature blood cells 
(Medvinsky, Rybtsov et al. 2011). At day E10.5, HSCs isolated from AGM possessed 
long-term reconstitution ability into irradiated adult mice (Medvinsky and Dzierzak 
1996). Approximately one dHSC was isolated from the 11.5 AGM, placenta and yolk 
sac, and by E12 the total number of mouse dHSCs was increased dramatically and 
around 80% was found in the fetal liver (Kumaravelu, Hook et al. 2002; Gekas, 
Dieterlen-Lievre et al. 2005)(figure1.1). 
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Figure ‎1-1 The main sites of mouse embryonic haematopoiesis. 
The figure was adopted from Orkin et al. (Orkin and Zon 2008) and illustrates the main sites 
of mouse embryonic haematopoiesis. Yolk sac blood islands are visualized by LacZ staining 
of transgenic embryo expression GATA-1- driven LacZ. AGM and fetal liver are stained by 
LacZ in Runx1-LacZ knockin mice. 
 
1.1.2 Adult Haematopoiesis  
 
In adult, BM represents the main site of haematopoiesis and provides the 
proper environment for the maintenance and differentiation of HSCs. However, 
some blood cells are maturated at sites other than BM such as T and B cells at the 
thymus and spleen, respectively. Today, cell surface antibodies and multicolour 
flow cytometry analysis have shown that haematopoiesis is a developmental 
hierarchy system with HSC at the top and differentiated cells on the bottom. The 
Weissman model proposes that long term HSCs (LT-HSC) are at the top of the 
hierarchy, which possess life-long self-renewal as well as multi-lineage 
differentiation potential. These cells are phenotypically defined as LIN–IL-7Rα– 
SCA1+KIT+FLT3–Thy1lowCD34– and are present at a low frequency in the BM (figure 
1.2 A) (Osawa, Hanada et al. 1996; Adolfsson, Borge et al. 2001; Weissman, 
Anderson et al. 2001). LT-HSCs give rise to limited self-renewal cells called short-
term HSCs (LIN–IL-7Rα– SCA1+KIT+FLT3lowThy1lowCD34+) (Morrison, Uchida et al. 
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1995; Christensen and Weissman 2001). Multipotent progenitors (MPP: LIN–IL-7Rα–
SCA1+KIT+FLT3 low–hi Thy1–CD34+) represent the next distinct populations, which are 
able to differentiate into all blood cell lineages. Signalling lymphocytic activation 
molecule (SLAM) family markers were also used to enhance the purification of 
mouse HSCs.  Within the LSK (LIN- SCA1+KIT+) population, LT-HSCs were highly 
purified as CD150+CD48- cells while MPPs were CD150-CD48- (Forsberg, Prohaska et 
al. 2005; Kiel, Yilmaz et al. 2005; Kiel, Yilmaz et al. 2008; Oguro, Ding et al. 2013). 
Recently, it has been shown that the LSK populations can be subdivided into four 
fractions according to their CD150 and CD48 expressions: HSC (CD150+CD48-), MPP 
(CD150-CD48-), haematopoietic progenitor cell-1 (HPC-1) (CD150-CD48+) and 
haematopoietic progenitor cell-2 (HPC-2) (CD150+CD48+) (Oguro, Ding et al. 2013).  
Common lymphoid progenitors (CLP: LIN–IL-7Rα+SCA1loKITlo) are considered as the 
first lymphoid progenitor that lost all myeloid differentiation potential and have the 
capability to form all the lymphoid cells (Kondo, Weissman et al. 1997). The 
Weissman model also proposes that all myeloid and erythroid cells arise from a 
group of progenitors called common myeloid progenitors (CMP: LIN–SCA1–
KIT+CD34+FcγRIIFcγRIIIlo). CMPs differentiate into more specified progenitors such 
as megakaryocyte/erythroid progenitor (MEP: LIN–SCA1–KIT+CD34–FcγRIIFcγRIIIlo) 
and granulocyte/monocyte progenitor (GMP: LIN–SCA1–KIT+ 
CD34+FcγRIIFcγRIIIhi)(Akashi, Traver et al. 2000). However, this view has been 
challenged by Jacobsen and colleagues who proposed that MEP can also be a direct 
progeny of ST-HSC which lacks FLT3 expression and do not go through CMP stage. 
In addition, their model demonstrated that MEPs are separated from lymphoid-
primed multi-potent progenitors (LMPPs), which represent the shared precursors of 
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both lymphoid and myeloid lineages (figure 1.2 B)(Adolfsson, Mansson et al. 2005; 
Yang, Bryder et al. 2005).    
 
 
Figure ‎1-2 The current concept of adult haematopoiesis 
The figure adopted from Rosenbauer et al. (Rosenbauer and Tenen 2007) and Illustrates 
the current concept of adult haematopoiesis. (A): A diagram represents the model 
established by the Weissman’s group.  LT-HSC: Long term haematopoietic stem cell; ST-
HSC: short term haematopoietic stem cells; MPP: multipotent progenitor; CLP: common 
lymphoid progenitor; CMP: common myeloid progenitor; GMP: granulocyte/monocyte 
progenitor; MEP: megakaryocyte/erythroid progenitor. (B) A diagram represents the 
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1.1.3 Transcription Factors in Haematopoietic Development 
 
Transcription factors have been defined as proteins that are able to bind to 
specific DNA sequences of a gene and regulate its transcription either positively or 
negatively (Latchman 1997). Several transcription factors have been found to play 
crucial roles during embryonic and adult haematopoiesis. For instance, generation 
of fetal liver HSC from the mesoderm requires stem-cell leukaemia factor (SCL) and 
runt-related transcription factor1 (RUNX1/AML1) (Shivdasani, Mayer et al. 1995; 
Okuda, van Deursen et al. 1996). However, a much milder impact on maintenance 
and self-renewal of adult HSCs was observed when SCL was conditionally 
inactivated in these cells suggesting that some transcription factors which are 
essential during embryonic haematopoiesis may be not required at the adult stage 
(Mikkola, Klintman et al. 2003). Furthermore, the formation of myeloid cells is 
maintained by different transcription factors such as PU1, growth-factor 
independent 1 (GFI1), CCAAT/enhancer binding protein-α (C/EBPα) and interferon-
regulatory factor 8 (IRF8)(figure 1.3) (Holtschke, Lohler et al. 1996; Yamanaka, 
Barlow et al. 1997; Hock, Hamblen et al. 2003; Dakic, Metcalf et al. 2005). Whereas 
PU1 expression is essential for CMP formation, it seems that C/EBPα is totally 
dispensable as mice deficient for this gene have normal number of CMPs but lacked 
GMPs and all subsequent lineages (Zhang, Zhang et al. 1997).  In zebrafish, myeloid 
and erythroid/megakaryocytic/eosinophil differentiations have been found to be 
promoted by PU1 and GATA1, respectively. The two proteins are physically 
interacting and affect each other’s function as inhibition of GATA1 expression 
resulted in haematopoietic shift to the myeloid fate, whereas the opposite affect 
 Chapter 1 Introduction  
22 | P a g e  
 
was observed upon inhibition of PU1 (Galloway, Wingert et al. 2005; Rhodes, Hagen 




Figure ‎1-3 The requirement of some transcription factors during haematopoiesis.  
The figure adopted from Orkin et al (Orkin and Zon 2008)and illustrates the requirement of 
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1.2 Core binding factor 
 
Core binding factor (CBF) is a heterodimeric transcription factor complex 
composed of two subunits, alpha and beta. In mammals, the alpha subunit is 
encoded by three genes, AML1, 2, 3, which are also known as RUNX1, 2, 3, whereas 
only one gene encodes the beta subunit CBFB. The alpha subunit represents the 
DNA binding element of the complex and its binding affinity is significantly 
increased in the presence of the beta subunit (Hart and Foroni 2002; de Bruijn and 
Speck 2004; Link, Chou et al. 2010). This complex performs a crucial role during 
haematopoiesis through regulation of different haematopoietic target genes such 
as granulocyte-macrophage colony stimulating factor (GM-CSF) (Takahashi, Satake 
et al. 1995), interleukin 3 (IL-3)(Shoemaker, Hromas et al. 1990), colony stimulating 
factor 1 (CSF1/M-CSF)(Zhang, Fujioka et al. 1994) and T-cell antigen receptors 
(TCRs)(Redondo, Pfohl et al. 1992).  Moreover, knock-out studies have shown that 
both AML1 and CBFβ are essential for definitive haematopoiesis and mice lacking 
these genes died at E12.5 with nearly identical phenotypes suggesting that both 
subunits are required and collaborate to maintain a common function at least 
during fetal haematopoiesis (Sasaki, Yagi et al. 1996; Wang, Stacy et al. 1996; Wang, 
Stacy et al. 1996). Furthermore, the two genes are among the most frequent 
targets of chromosomal translocations in leukaemia such as t(8;21), t(12;21), 
Inv(16)(p13;q22) and t(16;16)(p13;q22).  
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1.2.1 CBF alpha and beta subunits 
1.2.1.1 AML1 (RUNX1) 
 
Acute myeloid leukaemia 1 (AML1), also known as CBF alpha2, Polyomavirus 
enhancer binding protein 2 alpha (PEBP2alphaB) and runt-related transcription 
factor 1 (RUNX1), was first cloned using DNA isolated from a t(8;21) leukemic 
patient (Miyoshi, Shimizu et al. 1991). In human, the RUNX1 gene is located on 
chromosome 21 and can be transcribed from two alternatives promoters (distal 
(P1) and proximal (P2)). Consequently, different isoforms of RUNX1 can be 
synthesized by alternative splicing (figure 1.4)(Blyth, Cameron et al. 2005; Lam and 
Zhang 2012). In general, there are three main protein isoforms of RUNX1, (RUNX1a, 
RUNX1b, and RUNX1c) which are all characterized by the presence of 128 amino 
acids runt homology domain (RHD) at their N-terminal region. This domain is 
responsible for both DNA binding and heterodimer formation with the beta 
subunit. In addition, this domain interacts with several proteins such as ETS family, 
C/EBP alpha GATA1 and SMAD3 (figure 1.5). RUNX1 contains 31 amino acids at the 
C- terminal end called a nuclear matrix targeting signal (NMTS), which is responsible 
for transcriptional activation.  On the other hand, a VWRPY motif at the C-terminus 
mediates its Groucho/TLE-dependent transcriptional repressor activity (figure 1.5).  
Messenger RNAs (mRNAs) from both RUNX1a and RUNX1b are transcribed from the 
proximal (P2) promoter encoding for 250 and 453 amino acids proteins, 
respectively. Although, they are transcribed from the same promoter, their c-
terminal regions are different in which the transactivation domain is missing in the 
RUNX1a protein. RUNX1c represents the longest isoform as its transcript is 
transcribed from the distal (P1) promoter (figure 1.4). 
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Interestingly, various RUNX1 isoforms seem to play specific roles during 
haematopoiesis based on the site of transcription. For instance, knock-in studies 
using reporter genes for P2 (hCD4) and P1 (GFP) promoters in embryonic stem cell 
(ES) have shown that P2 promoter may play a crucial role for initiation of definitive 
haematopoiesis from hemogenic endothelium while the P1 promoter might be 
active in more mature progenitor cells. Moreover, Runx1 P1 null mice, in which 
sequences for P1 promoter and exon1 were replaced with neor cassette, were born 
alive with reduction in PB white blood and platelet cells, whereas offspring with 
severe reduction in P2 activity died shortly after birth (Sroczynska, Lancrin et al. 
2009; Bee, Swiers et al. 2010). Furthermore, RUNX1a was found abundantly 
expressed in CD34+ progenitors in human cord blood and over expression of this 
isoform using retroviral approach into mouse primitive haematopoietic cells has 
potentiated their engraftment ability (Tsuzuki, Hong et al. 2007). However, another 
study showed that RUNX1 over-expressed murine bone morrow mononuclear cells 
were able to induce lymphoblastic leukaemia into lethally irradiated mice (Liu, 
Zhang et al. 2009), suggesting that elevated RUNX1 increases engraftment abilities 
and may lead to haematopoietic malignancies. 
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Figure ‎1-4 The RUNX1 (AML1) isoforms 
The figure adopted from Lam et al (Lam and Zhang 2012) and shows RUNX1 isoforms. (A) 
The genomic locus of RUNX1 on chromosome 21 with the location of the proximal and 
distal promotors. (B) The three main transcriptional isoforms of RUNX1. (C) The three main 
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Figure ‎1-5 The RUNX1 (AML1b) domains 
The figure adopted from Lam et al (Lam and Zhang 2012) and shows RUNX1 domains in 
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Core Binding Factor Beta subunit (CBFB), also known as Polyomavirus Enhancer-
Binding Protein 2 Beta Subunit (PEBP2B), is the beta subunit of the core binding 
factor heterodimeric complex. This complex regulates several genes specific to 
haematopoiesis (RUNX1) and osteogenesis (RUNX2). Although, the beta subunit is a 
non-DNA binding regulatory element, it enhances the affinity of Runt domain for 
DNA binding (Tang, Crute et al. 2000; Yan, Liu et al. 2004; Li, Lukasik et al. 2006). In 
human, CBFB gene is located on chromosome 16 and two mRNA variants differed in 
their carboxyl terminus are generated by alternative splicing. Two proteins 
isoforms, one and two, of CBFB were detected in human encoding 187 and 182 
amino acids, respectively. The two proteins contain the alpha subunit 
heterodimerization domain which spans exons one, two, three, four and three 
amino acids from exon five (1-135 amino acids, figure 1.6), however the functional 
difference between these two isoforms remains unclear. In murine, there are four 
isoforms of Cbfb that encode proteins, CBFβ (p22) and CBFβ (P21.5) that containing 187 
and 182 amino acids, respectively. These two proteins were able to heterodimerize 
efficiently with the alpha subunit (CBFα) in vitro (Ogawa, Inuzuka et al. 1993; Wang, Wang 
et al. 1993; Miller, Stacy et al. 2001). The third isoform is CBFβ (p18) that lacks amino acids 
encoded in exon 5 resulting in a truncated protein (155 amino acids). The fourth isoform is 
CBFβ (p17.6) that lacks amino acid encoded in exon 3 and fails to bind with CBFα (Wang, 
Wang et al. 1993; Kagoshima, Akamatsu et al. 1996). Although CBFβ on its own does not 
bind to the DNA, the interaction between CBFβ and the runt domain of the AML 
protein stabilizes the association of this complex (Kim, Sieweke et al. 1999). 
Moreover, the N-terminal 141 amino-acid fragment of CBFβ protein was able to 
 Chapter 1 Introduction  
29 | P a g e  
 
rescue definitive haematopoiesis in CBFβ-deficient embryonic stem cells suggesting 
the importance of the heterodimerization domain for the in vivo function(Miller, 
Stacy et al. 2001).  
 
Figure ‎1-6 A diagram showing the heterodimerization domain of CBFβ protein 
The figure shows the structure of CBFβ protein and its heterodimerization domain which is 
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1.2.2 Expression Patterns of CBF 
 
Runx1 was found to be expressed at different sites and cells during 
embryogenesis and adult haematopoiesis. North et al  (North, Gu et al. 1999) 
showed that Runx1 expression was detected in the endothelial cells of different 
embryonic haematopoietic sites such as the yolk sac, the para-aortic 
splanchnopleura (PAS), the aorta-gonad mesonephros (AGM), and the vitelline and 
umbilical arteries. All the bone morrow haematopoietic stem and progenitors cells 
including the long term repopulating HSCs, colony forming units-spleen (CFU-S) and 
most of colony forming unit- cultures (CFU-Cs) express Runx1. Although, dendritic 
cells and mature macrophages expressed Runx1, this expression was rapidly 
declined in terminal differentiated cells such as erythrocytes and granulocytes 
(Basecke, Feuring-Buske et al. 2002; Lorsbach, Moore et al. 2004; North, Stacy et al. 
2004). In T-cell development, most of cells in the double negatives stages (DN1 
(CD44+CD25-), DN2 (CD44+CD25+), DN3 (CD44-CD25+)) expressed Runx1 protein 
whereas cells at the DN4 (CD44-CD25-) stage showed a reduced expression level. 
Both double positive (DP) (CD4/CD8) cells and single positive (SP) cells expressed 
Runx1 mRNA as well as the protein. The B220+ bone morrow cells differentially 
expressed Runx1 based on their maturation status as the highest percentage of 
Runx1+ cells was found in the pre-pro-B-cell population whereas the lowest 
percentage was in the pre-B-cell population (Basecke, Feuring-Buske et al. 2002; 
Lorsbach, Moore et al. 2004; North, Stacy et al. 2004).  
Kundu and colleagues were able to study the expression of Cbfb at the 
single-cell level using a knock-in approach in which Cbfb coding sequences are fused 
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to those of GFP (Kundu, Chen et al. 2002). Cbfb was expressed in all of the major 
embryonic sites of haematopoiesis (yolk sac, liver, AGM) as well as the adult one 
(BM, lymph node, spleen, thymus). In addition, Cbfb was detected in Lin- c-kit+ bone 
morrow population, which is enriched for haematopoietic stem and progenitor cells 
as well as in CFU-Cs, megakaryocytes, monocytes and granulocytes.  Similarly to 
Runx1, Cbfb expression rapidly declines in the definitive erythroid as the Ter119+ 
cells show no expression.  All T-cell populations were found to express a uniform 
level of Cbfb. In B-cell development, the highest level of Cbfb was found similarly to 
Runx1 in pre-pro-B cells while the pre-B cells showed low expression (Kundu, Chen 
et al. 2002; Taniuchi, Osato et al. 2002).  
1.2.3 Structure and Interaction 
 
The interaction between Runx1 and CBFβ is considered as a pivotal step for 
their normal functions as well as for their roles in haematopoiesis.  Warren and his 
group gained important insight into this interaction by co-expressing human protein 
fragments of RUNX1 (residues 50-183) and CBFβ (residues 2-135) in E. coli.   The 
overall structure showed that the runt domain of RUNX1 forms 12 stranded β 
barrels, whereas the CBFβ subunit was composed of both α/β structures (Warren, 
Bravo et al. 2000). The α/β structures of CBFβ are consisting of six-stranded β-
sheets packed on one another surrounded by four peripheral α-helices (Huang, 
Peng et al. 1999; Warren, Bravo et al. 2000; Zhang, Lukasik et al. 2003) (figure 1.7). 
Moreover, the complex was arranged as six runt domains with four CBFβ subunits 
as two dimers of runt domain-CBFβ heterodimers and a homo-dimer runt domain. 
In addition to the DNA binding enhancement of the runt domain upon the 
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interaction, CBFb was found to be fundamental for protecting RUNX1 from 
ubiquitin-proteasome degradation (Huang, Shigesada et al. 2001).  
 
                           
Figure ‎1-7 A diagram showing the α-helices and β-strands of CBFβ protein 
The figure adopted from Huang et al (Huang, Peng et al. 1999) shows a ribbon 
representation of CBFβ (141). Red and yellow colours represent the α-helices whereas the 
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1.2.4 Role of CBF in Haematopoiesis 
1.2.4.1 Embryonic Haematopoiesis 
 
Three studies by Wang et al 1996, Sasaki et al 1996, and Niki et al 1997 
(Sasaki, Yagi et al. 1996; Wang, Stacy et al. 1996; Niki, Okada et al. 1997) were 
carried out to investigate the role of Cbfb in embryogenesis and also to study its 
impact on haematopoiesis. In spite of the failing attempt to disrupt exons 4 and 5 of 
the Cbfb gene in Wang’s study, they were able to create a hypomorphic Cbfb allele 
by replacing the 5’ half of exon 5 with neor gene. Similar strategy was considered in 
Sasaki’s work in which they were able to replace exon 5 with a neor gene. Mice 
heterozygous for this mutation were inbred and their progeny were analysed. Cbfb 
homozygous mutant embryos were able to express only a truncated protein which 
was weakly associated with the alpha subunit. Live offspring homozygous for this 
mutation were not obtained and all embryos died at E12.5 due to haemorrhage in 
the central nervous system and impairment in the fetal liver haematopoiesis. Niki 
and his colleagues were able to disrupt the Cbfb gene through replacing the first 
exon with neor gene, and as a result neither transcripts nor proteins of Cbfb gene 
were synthesised. All the data demonstrated that fetal liver haematopoiesis was 
severely disrupted and this finding was confirmed by liver sections stain, 
methylcellulose colony forming assay and RT-PCR. Liver sections from E12.5 WT and 
heterozygous Cbfb mutated embryos showed abundance of haematopoietic 
progenitors, nucleated and non-nucleated erythrocyte inside the sinusoidal cavities. 
In contrast, the homozygous mutated Cbfb embryos contained very few erythroid 
and myeloid progenitors and lack mature erythrocytes. Moreover, in contrast to WT 
Cbfb controls, no differentiation of definitive erythroid, myeloid and mix colonies 
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from cells isolated from yolk sacs and livers of the homozygous mutated Cbfb 
embryos could be observed. Furthermore, RT-PCR data showed yolk sac cells 
isolated from the mutated embryos lacked expression of key genes, which are 
essential for definitive haematopoiesis such as c-myb, gata2 and flt3. The results of 
these three studies are very similar to the Runx1 knock out data (Okuda, van 
Deursen et al. 1996; Wang, Stacy et al. 1996; Okada, Watanabe et al. 1998) 
suggesting that the full length Cbfb transcript may perform a crucial function, which 
is missing in the truncated protein. 
1.2.4.2 Adult Haematopoiesis  
 
In contrast to the crucial role of Runx1 during embryogenesis, several 
studies have demonstrated that Runx1 was not essential for adult haematopoiesis 
as the conditionally deleted Runx1 mice were viable (Ichikawa, Asai et al. 2004; 
Growney, Shigematsu et al. 2005; Motoda, Osato et al. 2007; Ichikawa, Goyama et 
al. 2008; Schindler, Van Buren et al. 2009; Jacob, Osato et al. 2010; Cai, Gaudet et 
al. 2011). However, there were a number of haematopoietic abnormalities which 
were observed during analysis of the Runx1 deficient mice. For instance, the 
numbers of LSK cells were elevated in the bone morrow of Runx1 deleted Mx1-cre 
mice. Moreover, these mice had defects in B cell development as there was around 
20% reduction in the percentage of mature B cells (CD19+ B220+) with severe 
reduction in pre-B and pro-B cells. T-cell development was also affected upon 
deletion of Runx1 by three fold reduction in DN3, DN4 and around 40% reduction in 
the percentage of DP cells(Ichikawa, Asai et al. 2004). Although, the number of in 
vitro CFU-Meg was elevated, the deleted mice showed severe impairment of 
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platelet production and megakaryocyte differentiation, suggesting the requirement 
of Runx1 for megakaryocyte maturation (Ichikawa, Asai et al. 2004; Growney, 
Shigematsu et al. 2005). It seems Runx1 is not critical for the terminal maturation of 
granulocyte and monocyte as mice lacked its expression had morphologically 
normal mature myeloid cells. Interestingly, Runx1 deficient mice had a mild myeloid 
expansion in their haematopoietic tissues in addition to a myeloproliferative 
phenotype, which is consistent with the identification of RUNX1 mutations in 
human myeloid malignancies (Bejar, Stevenson et al. 2011). Histological 
examinations of both spleen and liver of the Runx1 deleted mice showed 
extramedullary haematopoiesis, however spontaneous leukaemia was not 
observed in these mice (Growney, Shigematsu et al. 2005).   
The role of Runx1 in HSC function is not clear as different groups have 
reported opposing effects of Runx1 deletion on the numbers of LT-HSC (Ichikawa, 
Goyama et al. 2008; Schindler, Van Buren et al. 2009; Cai, Gaudet et al. 2011). Using 
the Hoechst 33342 side population gating strategy, Ichikawa et al showed that the 
Runx1 deficient bone morrow had more quiescent HSCs and concluded their study 
by demonstrating the negative impact of Runx1 on quiescent HSCs (Ichikawa, 
Goyama et al. 2008). On the other hand, Schindler et al used SLAM markers to 
analyse the Runx1 deleted mice and they observed a significant reduction in LT-
HSCs (Schindler, Van Buren et al. 2009).  
Although two different Runx1 mouse models were used in these studies, it 
seems that the number of phenotypic and functional LT-HSCs depends on the 
criteria as well as the markers used to define them. In fact, this was demonstrated 
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by Cai et al who used both SLAM and CD34- flt3- LSK markers to study the effect of 
Runx1 deletion on adult haematopoiesis. In contrast to the severe reduction in 
SLAM-marked phenotypic LT-HSCs, they found a 2 fold increase on LT-HSCs upon 
using CD34- Flt3- LSK markers (Cai, Gaudet et al. 2011). Unexpectedly, the mean 
fluorescence intensity (MFI) of CD150 and CD48 in the Runx1 deleted LSK flt3- cells 
were significantly higher, despite the fact that their Slamf1 (CD150) and CD48 
mRNA levels were low or unchanged, respectively. In fact, these data forced them 
to stain the analysed cells using all the markers (SLAM, CD34, flt3, LSK) and they 
found the CD34 FLt3 LSK-marked phenotypic LT-HSCs were shifted upwards on the 
CD48 axis and did not fall within the CD48- gate. These results suggest that upon 
Runx1 deletion several commonly used LT-HSC markers are dysregulated, therefore 
their reliability for defining of phenotypic HSCs may be challenged.   
At the start of my PhD, the role of Cbfb in adult haematopoiesis remains 
poorly understood especially in the myeloid compartments. Therefore, this PhD 
was also aimed to investigate the role of Cbfb in adult haematopoiesis using 
conditionally knockout mice. Talebian et al (Talebian, Li et al. 2007) studied the role 
of Cbfb in haematopoiesis using a hypomorphic Cbfb allelic series, in which they 
were able to reduce the level of Cbfb by 3 to 6- folds. This reduction caused 
abnormalities in megakaryocytes, granulocytes and bone development. T-cell 
development was severely impaired as the mature thymocytes were virtually 
absent when Cbfb was reduced by 6-folds. Moreover, differentiation blocks were 
observed during the early T-lineage progenitors in particular within the DN1 and 
DN2 subsets. Furthermore, the Cbfbf/f:Lck mice showed approximately 2-folds 
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reduction at the DN stage with severe impairment of mature thymocytes. In 
contrast, a moderate reduction of mature thymocytes was observed in Cbfbf/f:Cd4 
mice (Naoe, Setoguchi et al. 2007). These data suggest that the level as well as the 
spatial deletion of Cbfb may play a critical role during adult haematopoiesis.  
 
1.2.5 Role in Solid tumours  
 
Recently, the next-generation sequencing and SNP array analysis have 
shown that both RUNX1 and its heterodimeric partner, CBFB, were mutated in 
breast cancer (Banerji, Cibulskis et al. 2012; Ellis, Ding et al. 2012). In addition, 
RUNX1 deletion was also observed in oesophagus cancer (Dulak, Schumacher et al. 
2012). CBFβ was found to be expressed in the metastatic breast cancer cell line 
(MDA-MB-231) and targeting its expression using siRNA or shRNA resulted in less 
invasive cells (Mendoza-Villanueva, Deng et al. 2010). Moreover, the growth of two 
prostate cell lines (PPCI and PC-3) and the SKOV-3 ovarian cell line was significantly 
inhibited upon knockdown of CBFβ (Davis, Rogers et al. 2010). Thus, it seems that 
CBFβ contributes to the invasive capability of these cell lines and targeting its 
expression may represent a promising therapeutic strategy for some human 
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1.2.6 Role in Leukaemia 
 
The RUNX1 and CBFB genes are the most frequent targets for chromosomal 
translocations in leukaemia generating AML1-ETO (AE) fusion and CBFβ-SMMHC 
fusion in t(8;21) and inv(16) AMLs, respectively.  
1.2.6.1 AML1-ETO 
 
AML1-ETO (also known as RUNX1-ETO, RUNX1-RUNX1T1 and RUNX1-MTG8) 
is one of the most frequent chromosomal translocation in human leukaemia and is 
found in 5-10% of AML (Zeisig, Kulasekararaj et al. 2012). This translocation joints 
together sequence of RUNX1 on chromosome 21 with that of ETO on chromosome 
8, t(8,21).  Its breakpoints occur in intron 5 of RUNX1 gene and in either intron 1a or 
1b of the ETO gene.  The common form of AML1-ETO fusion protein consists of 752 
amino acids containing the N-terminal of AML1 protein, in which the runt domain is 
included, and almost the entire transcriptional repressive ETO protein (Tighe and 
Calabi 1994; Tighe and Calabi 1995; Zhang, Strissel et al. 2002). As shown in figure 
1.8, four Nervy homology regions (NHR) are characterizing the ETO part, which 
share the Drosophila Nervy protein. 
These NHRs are responsible for the interaction of ETO with other proteins. 
For instance, NHR1 interacts with E proteins and inhibits their ability to recruit 
some co-activator molecules such as p300/CBP (Zhang, Kalkum et al. 2004) . NHR2 
and NHR4 interact with co-repressors like mSin3a, NCoR/SMRT and HDACs 
(Lutterbach, Westendorf et al. 1998; Wang, Hoshino et al. 1998; Zhang, Hug et al. 
2001).  
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Figure ‎1-8 The structure of AML1-ETO and its interaction partners. 
The figure modified from Lam et al (Lam and Zhang 2012) which illustrates structure of 
AML1-ETO and its interaction partners.  
 
 
Multiple isoforms of AML1-ETO were detected in AML patient samples, 
most of them contained the full length (752 amino acids). Interestingly, AML1-ETO 
truncated isoform, which has 552 amino acids, was able to induce leukaemia 
rapidly in mice, suggesting the C-terminal of the full length may act as an inhibitor 
for the leukaemogenesis of this protein (Yan, Burel et al. 2004) as full length AML1-
ETO cannot induce leukemia in mice. Also, another AML1-ETO transcript, which 
included an extra exon (9a), was detected in AML patients (figure 1.9). Contrasting 
to the full length, this transcript was also able to induce leukaemia in a mouse 
model (Yan, Kanbe et al. 2006). 
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Figure ‎1-9 Structures of the main three AML1-ETO isoforms. 
 
Several models have been used to investigate the impact of AML1-ETO on 
haematopoiesis. For instance, inducible expression of AML1-ETO in a transgenic 
zebrafish model recapitulated some phenotypes seen in AML patients such as 
accumulation of blasts cells and disruption of normal haematopoiesis (Yeh, Munson 
et al. 2008). Zhang and colleagues developed the first mouse model using a Knock-
in approach, in which the AML1-ETO fusion gene was inserted into the AML1 locus 
(Yergeau, Hetherington et al. 1997; Okuda, Cai et al. 1998). Heterozygous AML1-
ETO mice died embryonically with phenotypes most similar to that revealed by 
AML1 and Cbfβ KO mice. Although AML1 KO mice entirely lacked definitive 
haematopoiesis, yolk sac and fetal liver cells isolated from the heterozygous AML1-
ETO embryos were able to differentiate into macrophage and dysplastic myeloid 
cells, respectively (Yergeau, Hetherington et al. 1997; Okuda, Cai et al. 1998). In 
addition, transgenic AML1-ETO mice under the control of several promoters such as 
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MRP8 and a tetracycline-responsive element have been also generated; however 
these mice were healthy and displayed a normal haematopoiesis and failed to 
develop leukaemia (Rhoades, Hetherington et al. 2000) without induction of 
additional mutations by treating these mice with N-ethyl-N-nitrosourea resulted in 
AML (Yuan, Zhou et al. 2001). Similar results were observed by another group after 
using conditional AML1-ETO Knock-in mice and Mx1-Cre inducible system (Higuchi, 
O'Brien et al. 2002). 
Retroviral transduction and transformation assay was conducted to 
investigate the effect of AML-ETO on normal haematopoiesis. Although immature 
blast cells and inhibition of myeloid differentiation were observed, spontaneous 
AML development did not occur (de Guzman, Warren et al. 2002; Schwieger, Lohler 
et al. 2002). Xenograft models, in which human CD34+ cells were transduced with 
AML1-ETO and transplanted in to NOD/SCID mice, had demonstrated that AML1-
ETO alone was able to enhance self-renewal but incapable to induce leukaemia 
(Mulloy, Cammenga et al. 2003; Basecke, Schwieger et al. 2005). These data reveal 
that the AML1-ETO may have additional properties, which promote 
leukaemogenesis, rather than simply acting as a dominant negative regulator of 
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1.3 Leukaemia stem cells (LSCs)  
 
Decades ago, it was postulated cancers might be originated from subset of 
cells that have stemness properties (Makino 1959; Hamburger and Salmon 1977; 
Salmon, Hamburger et al. 1978). However, this has not been fully characterized 
until recent years with the advance in FACS analysis and transplantation models.  
The presence of LSC was firstly demonstrated in acute myeloid leukaemia (AML), in 
which the existence of a small number of phenotypically distinctive leukemic cells is 
responsible for generating the disease in xenograft models. For instance, Bonnet 
and Dick demonstrated that a small fraction of primitive cells (Lin-CD34+CD38-) was 
able to induce the disease in NOD/SCID mice with a phenotype similar to the one 
observed in patients. In addition, these cells were also able to induce AML in 
secondary recipients, demonstrating their self-renewal ability. On the other hand, 
mature cells (Lin-CD34+CD38+ or CD34-) failed to transfer the disease. Therefore 
they concluded their study by suggesting that the target of leukeamic 
transformation is normal primitive cells rather that progenitor cells (Bonnet and 
Dick 1997). However, several studies later on showed that some progenitor cells 
can be transformed by some oncogenes and also were able to induce AML in mice. 
Using RTTA, So et al. clearly demonstrated that MLL-GAS7 can transform 
multipotent haematopoietic progenitors leading to the induction of mixed lineage 
leukaemia in mice, but not CMP or CLP progenitors (So, Karsunky et al. 2003). 
Cozzio and colleagues were able to demonstrate that MLL-ENL can transform CMP 
and GMP in vitro and these cells induced leukaemia in vivo with latencies similar to 
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the MLL-ENL HSC transformed cells (Cozzio, Passegue et al. 2003). Recently, Heuser 
et al demonstrated that CMP cells were able to be transformed by MN1 and also to 
generate leukaemia in vivo, whereas GMP cells were unable (Heuser, Yun et al. 
2011).   
It has been demonstrated that LSCs may home in the microenvironment of 
the BM where they will maintain quiescent at G0 stage (Guan, Gerhard et al. 2003; 
Ishikawa, Yoshida et al. 2007). Consequently, chemotherapy treatment that targets 
highly dividing cells (bulk disease) has a minimum impact in eliminating the LSCs 
which causes the relapse. Indeed, developing better curative therapies for 
leukaemia requires not just full understanding of the LSCs properties, but also their 
main differences with the bulk population and the normal HSCs.                
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1.4 Objectives 
AML1 and CBFB are the most frequent targets for chromosomal 
translocations in acute myeloid leukaemia generating AML1-ETO (AE) fusion and 
CBFβ-SMHCC fusion, respectively. Although, Cbfb enhances the binding affinity of 
AML1 to DNA, its role in AE-mediated transformation remains unclear. Recent 
studies by others (Park, Speck et al. 2009; Roudaia, Cheney et al. 2009) and our 
group (Kwok, Zeisig et al. 2009; Kwok, Zeisig et al. 2010) using Cbfb-interaction 
defective AE mutants in different experimental settings have yielded conflicting 
results.  The role of Cbfb in AE-mediated leukaemogenesis remains unclear. In 
addition, while AML1 and Cbfb have a pivotal role during embryonic 
haematopoiesis, the function of Cbfb in adult haematopoiesis is still not fully 
understood. Definition of Cbfb requirement is important for understanding the 
biology of the disease and also for designing better cancer therapeutics, in 
particular when inhibitors targeting Cbfb/AML1 interaction is being developed for 
this purpose (Gorczynski, Grembecka et al. 2007; Cunningham, Finckbeiner et al. 
2012). Thus in my PhD project, we aim to clearly define the role of Cbfb AE-
mediated leukaemogenesis and also in the development of normal HSCs.  
The main aims of the PhD project are the following: 
1- To define the role of Cbfb in AE in vitro transformation activity using primary 
bone marrow cells derived from mice carrying conditionally deleted Cbfb 
alleles.  
2- To investigate the role of Cbfb in AE‐mediated transformation in different 
haematopoietic stem/progenitors cells isolated from Cbfbf/fRosa26Cre ER. 
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3- To define the role of Cbfb in AE leukaemogenesis using fetal liver cells 
isolated from Cbfbf/fRosa26Cre ER. 
4- Establishing an in vivo AEs leukaemia models that allow us to study the 
impact of Cbfb deletion on initiation and maintaining this disease. 
5- To define the molecular function and downstream target of Cbfb involved in 
leukaemic transformation.  
6- To investigate the role of Cbfb in development of normal adult HSCs by 
targeting Cbfb in whole mouse versus only in the haematopoietic cells or the 
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2 Materials and methods 
2.1 Mice 
Cbfb flox mouse in a mixed background was a kind gift from Dr. Ichiro 
Taniuchi and the targeting strategy for generating this mouse is illustrated in figure 
2.1. The strategy was characterized by placing a floxed neomycin resistance 
cassette next to exon 5 and a loxP site to the other flanking intron. After 
introducing this mutation into embryonic stem cells, a transient expression of Cre 
recombinase was carried out to remove the neomycin resistance cassette. Thus, 
exon 5 of this transgenic mouse was flanked by loxP sites (figure2.1 (Naoe, 
Setoguchi et al. 2007)). At the beginning, Cbfβflox mouse was crossed with Rosa 26 
YFP mouse to generate Cbfβfl/fl Rosa 26 YFP/wt mouse and also backcrossed with 
C57BL/6 to generate a Cbfβflox   mouse in a pure background. In addition to this 
mouse strain, Cbfβfl/fl Rosa 26 Cre ER mice were generated by breeding Cbfβflox pure 
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Figure ‎2-1 Targeting strategy for generating Cbfb flox mouse 
(A) shows structures of the wild type cbfb, targeting vector and the targeted Cbfb neo loci. 
Black boxes and triangles indicate exons and loxP sequences, respectively. Bg, BgIII; K, KpnI; 
RI, EcoR1, HIII, HindIII; S, SaII; Sc, Sac1.  (B) Southern bot of embryonic stem cell clones 
(Naoe, Setoguchi et al. 2007).  
 
2.2 Genotyping  
 
Genomic DNA (gDNA) was isolated from ear biopsies of 5-week-old mice 
using Hotshot buffer. The ear samples were lysed in a hotshot lysis buffer 
containing (25mM NaOH and 0.2mM EDTA) for 20-30 minutes at 95oC and 
neutralized by adding equal amount of host shot neutralizing buffer (40mM Tric-
HCL). Cbfb floxed, deleted and wild-type alleles were detected by multiplex PCR 
with the following primers: G2, 5'-CCTCCTCATTCTAACAGGAATC-’3; G3, 5'-
GGTTAGGAGTCATTGTGATC AC-’3; and G6, 5'-CATTGGATTGGCGTTACTGG-'3 (figure 
2.2). PCR amplifications were carried out in a 20-µl reaction volume contained 1X 
Dream Green buffer supplemented with 2.5 mM MgCl2 (Fermentas), 0.25 mM dNTP 
mix (Roche), 1µM from each primer and 0.5 unit of Dream TaqTM Green DNA 
polymerase (fermentas). Thirty cycles of amplification were performed using the 
following PCR conditions: Hot start for 4 minutes at 94oC, denaturating for 30 
seconds at 94oC, annealing for 30 seconds at 540C, elongation at 72oC for 30 
seconds, and final elongation for 7 minutes at 72oC. Genotyping of Cbfβfl/fl Rosa 26 
YFP/wt and Cbfβfl/fl Rosa 26 Cre ER mice were carried out similarly to the floxed one 
using different primers as shown in table 2.1.  
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Figure ‎2-2 Locations of Cbfb primers (G2, G3 and G6). 
This diagram shows locations of Cbfb primers which were used for genotyping (Flox band: 
400bp, KO band: 300bp and WT band: 275bp). 
 Table ‎2-1 Primer sequences for genotyping of Cbfβfl/fl Rosa 26 YFP/wt and Cbfβfl/fl Rosa 
26 Cre ER mice. 
Mouse  Primers (5'-3') Annealing Temperature  








2.3 Cloning  
 
The retroviral plasmids (MSCV, Clontech) expressing different transcription 
factors such as AML1-ETO, AML1-ETO9a, MLL-AF9, MN1, hit and run cre were 
obtained from the clone database of our leukaemia and stem cell biology group 
(Kwok, Zeisig et al. 2009; Kwok, Zeisig et al. 2010; Yeung, Esposito et al. 2010; 
Smith, Yeung et al. 2011). Cbfb and exon 5-deleted Cbfb were cloned into pSG5 
vectors by isolating cDNAs from WT and deleted Cbfb cells, respectively. The cDNAs 
were amplified using primers having EcoRI and BamHI sites (F: 
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5’AAATTTGAATTCATGCCGCGCGTCGTCCCGGA3’,R: 5’AAATTTGGATCCTTAACGAAGTTTGAGATCATCACG 3’) 
(figure 2.3). Then, the digested cDNAs were cloned between the EcoRI and BamHI 
sites of the pSG5 vector.  
Similar strategy was performed to tag both the WT cbfb as well as the 
spliced isoform with HA tag and to clone them into pMSCV puro vector. Firstly, the 
cDNA templates were amplified using primers have Bgl II, HA sequences and EcoR1 
sites(F:5’AAATTTAGATCTATGTACCCATACGATGTTCCAGATTACGCTCCGCGCGTCGTCCCG3’,R:5’AAATTTGAATTCT
TAACGAAGTTTGAGATCATCACCG 3’). Then, the digested cDNAs were cloned between the Bgl 
II and EcoR1 sites of the pMSCV vector. All the DNA plasmids were prepared using 
Qiagen/Fermantas kits according to the manufacturer’s instructions.  
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2.4 Virus production 
 
One day before transfection,  4x106 GP2-293 cells (Clonetech) were seeded 
into a 10-cm plate with 8 ml of pre-warmed of (D10): Dulbecco’s Modified Eagle 
Medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, SIGMA), 
100 IU/ml of penicillin and streptomycin (SIGMA). The transfection was carried out 
by adding a mixture contained (414 µl of H2O, 15 µg of 1µg/µl of DNA construct, 
9µg of 1.0 µg/µl Vesicular Stomatitis Virus Glycoprotein Epitope (pVSV-G), 1µg of 
1µg/µl Green Fluorescent protein (GFP), 61µl of 2M Cacl2 and 500µl of 2X HBS onto 
the seeded GP2-293 cells. The transfected cells were incubated overnight at 37oC, 
5%CO2 and their efficiency were determined based on the percentage of GFP 
expression under the fluorescence microscope. Twenty-four hours after 
transfection, the old medium was replaced with 10ml pre-warmed D10 and the 48-
h virus were collected by aspirating the supernatant with 10ml syringe and filtered 
through a 0.45 µm filter. The virus was concentrated by using the OptimaTM L-100 
XP Ultracentrifuge (Beckman) at 25000 rpm, 4oC for 3 hours. The supernatant of the 
concentrated virus (3ml) was resuspended and stored in 500µl aliquots at -80oC 
until required.  
2.5 Isolation of c-kit+ (CD117) cells from mouse bone marrow 
 
The femurs and tibias of the experimental mice were isolated and 10ml of  
suspension medium (SM, PBS with 0.2% FBS and 100 IU/ml of penicillin and 
streptomycin) were used to flush the bone morrow into 15ml test tube using 10ml 
syringe attached with 25G needle (Terumo®, Belgium). The bone morrow cells were 
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centrifuged at 1300 rpm for 5 minutes at room temperature (Allegra® X-15R 
centrifuge, Bechman coulter). The cell pellet was resuspended in 1ml of red cell 
lysis buffer (10mM KHCO3, 150mM NH4Cl, and 0.1mM EDTA) and incubated for 10 
minutes at room temperature. This reaction was terminated by adding 10ml of SM 
and the cells were filtrated using 40µM cell strainer (BD FalconTM). Then, the cell 
pellet was resuspended in 500µl of SM and incubated with 15µl of c-kit 
beeds(MACS, MiltenyiBiotec) for 30 minutes at 4oC. At the end of the incubation, 
500µl and 30ml of SM were used to equilibrate the MS column and to wash the 
incubated cells, respectively. The cell pellet was resuspended with 500µl of SM and 
the mixture was applied to the equilibrated MS column which was attached onto a 
magnetic stand. Cells were washed twice with 500µL of SM and the MS column was 
transferred into 1.5ml microcentrifuge tube in which 1ml of SM was used to flush c-
kit+ cells using a plunger. 200µl of R10 supplemented with IL3, IL6 (10ng/ml) and 
SCF (20ng/ml) cytokines were used to plate the required number of c-kit+ cells in a 
96-well plate. Cells were incubated overnight at 37oC with 5% CO2 (Zeisig and So 
2009). 
2.6 Isolation of fetal liver cells 
 
Timed mating between Cbfb breeding pairs was set up in the late afternoon 
and the vaginal plug of the female was checked in the early morning of the next day 
to separate the male and also to start counting the days of conception. The 
embryos were aged E0.5 at noon of the day on which the vaginal plug was seen and 
we usually harvest the fetal live cells around E11.5-E15.5. The pregnant female was 
culled using CO2 chamber and under sterile conditions all the embryos were 
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collected into 50-ml tube contained PBS. Livers from foetuses were surgically 
removed into 15 ml tubes with 5 ml SM and passed several times through a syringe 
with an 18G and then 25G needles. The mixture was filtered using a 40µm cell 
strainer. Cells were centrifuged at 1300 rpm for 5 minutes at room temperature 
and the pellet was resuspended in 3ml of red cell lysis buffer for 5 minutes on ice. 
Cells were washed using 10ml of SM and cultured at 1-2x106/ml of RPMI medium 
supplemented with 10ng/ml IL3, IL6, 20ng/ml SCF, and 15% FBS. Fetal liver cells 
were incubated overnight at 37oC with 5% CO2. 
2.7 Sorting and analysing of haematopoietic stem/progenitors cells 
2.7.1 Sorting 
 
A protocol from Yeung and So (Yeung and So 2009) was adapted and slightly 
modified to sort haematopoietic stem/progenitor cells.  MNCs were isolated from 
five WT mice or KO mice and stained with primary lineage unconjugated rat IgG 
(Ter 119, Mac 1, Gr 1, CD3e, CD4, CD8 and B220, Biolegend ) at a dilution of 1:40. 
The stained cells were incubated at 40C for 30 minutes and then washed with SM. 
Cells were incubated with washed Dynabeads (sheep anti-rat IgG, Dynal, Invitrogen, 
120.21D) for 30 minutes at 4oC. At the end of the incubation, the magnet was 
applied to the mixture for 3 minutes and the unbound lineage depleted cells were 
transferred to a fresh 10 ml test tube.  Then, cells were stained with goat anti-rat-
PECy5.5 at a dilution of 1:50 to exclude cells that escaped the depletion process, 
and then washed with SM. Cells were blocked with rat IgG (Sigma) for 30 minutes at 
4oC. After that, cells were washed with SM and stained with secondary antibodies 
as indicated in table2.2. Stained Cells were washed and resuspended in SM with 
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1µg/ml of propidium iodine (PI), and then subjected to sort LSK (Lin –/low Sca1 + c-
Kit+), CMP (Lin –/low Sca1 – c-Kit + CD34 + CD16/32 low), GMP (Lin –/low Sca1 – c-Kit + 
CD34 + CD16/32 hi) and MEP (Lin –/low Sca1 – c-Kit + CD34- CD16/32 low) using ARIA cell 
sorter (BD Bioscience). Sorted cells were seeded in sterile 96-well plate contained 
R10 supplemented with cytokines (20ng/ml SCF, 10ng/ml of IL3 and IL6) and 
incubated overnight at 37oC with 5% CO2.  
The purity of the sorted stem/progenitor cells was assessed using Colony-
Forming Unit (CFU) assay in which 1000 cells from LSK, CMP, GMP and MEP were 
plated into a methylcellulose (STEMCELLTM) supplemented with 20 ng/ml SCF, 10 
ng/ml of IL3, IL6, GM-CSF, 100 IU/ml penicillin, 100 µg/ml streptomycin and 5 units 
of Erythropoietin. The cells were incubated at 37oC with 5% CO2 for 7-14 days and 
burst-forming unit-erythroid (BFU-E), colony-forming unit-granulocyte, macrophage 
(CFU-GM), Colony-forming unit-granulocyte (CFU-G), colony-forming unit-
macrophage (CFU-M), colony-forming unit-granulocyte, erythroid, macrophage, 
megakaryocyte (CFU-GEMM) colonies were scored.   
Table ‎2-2 Secondary antibodies and their dilutions that used to stain haematopoietic 
stem/progenitor cells for sorting. 
Antibody  Source/Clone Dilution  
c-Kit-PE Biolegend/2B8 1:100 
Sca1-PE-Cy7 eBioscience/D7  1:50 
CD34-FITC eBioscience/RAM34 1:25 
CD16/32-APC Biolegend/93 1:75 
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Haematopoietic stem/progenitor cells analysis was carried out similarly to 
the sorting protocol with slight modification. 3-4x106 MNCs from each mouse were 
used to conduct the analysis and the incubation with Dynabeads was skipped in this 
protocol. Cells were stained with secondary antibodies as illustrated in table 2.3. 
The stained cells were subjected to LSK, LT-HSC (LSK CD150+CD48-), ST-HSC (LSK 
CD150- CD48-) (Cai, Gaudet et al. 2011), LMPP (LSK CD150- CD48+), CLP (Lin –/low IL-
7R α + Sca1 lo c-Kit low), CMP, GMP and MEP analysis using ARIA (BD Bioscience) 
and FlowJo software. 
 
Table ‎2-3 Secondary antibodies and their dilutions that used to stain haematopoietic 
stem/progenitor cells for analysis 
Antibody  Source/Clone Dilution  
c-Kit-PE Biolegend/2B8 1:100 
Sca1-PECy7 eBioscience/D7  1:50 
CD34-FITC eBioscience/RAM34 1:25 
CD16/32-APC Biolegend/93 1:75 
CD150-BV421 Biolegend/TC15-12F12.2 1:25 
CD48-Alexa flour 700® Biolegend/HM48-1 1:50 
Biotin anti mouse IL-7 Biolegend/A7R34 1:100 
Streptavidin APC/cy7 Biolegend 1:50 
CD45.2-BV 650 Biolegend/104 1:50 
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2.8 Spinoculation and methylcellulose replating assay 
 
The spinoculation and methylcellulose replating protocol was adopted from 
Zeisig and So (Zeisig and So 2009). LSK, CMP, GMP, MEP or c-Kit seeded cells in 96-
well plate contained R10 supplemented with cytokines (20ng/ml SCF, 10ng/ml of 
IL3, IL6 and 10mg/ml of polybrene) were subjected to spinoculation with viruses 
carrying different leukaemia associated transcription factors. Spinoculation was 
carried out by centrifugation for 2 hours at 800g, 320C and then cells were 
incubated overnight at 37oC with 5% CO2. The transduced cells were transferred 
into 0.9 ml of pre-warmed methylcellulose (STEMCELLTM) supplemented with 20 
ng/ml SCF, 10 ng/ml of IL3, IL6, GM-CSF, 100 IU/ml penicillin, 100 µg/ml 
streptomycin and 1mg/ml geneticin or 1.3µg/ml puromycin. Cells were mixed well 
and transferred into one well of 24-well culture plate and incubated for 5-to 7 days 
at 37oC with 5% CO2 and then colonies of the 1
st round were scored. After that, 
colonies were harvested using 8 ml of SM and transferred into a 15 ml test tube and 
were centrifuged for 5 minutes at 1300 rpm, 20oC. Cells were counted and 1-2x104 
cells were re-plated into 0.9 ml methylcellulose supplemented with cytokines. This 
re-plating was carried out for 2nd, 3rd and subsequent rounds and after each round 
few cells were kept for genotyping, WB and RNA isolation.   
2.9 Co-immunoprecipition (Co-IP) 
 
To test the interaction between Flagged AE and HA tagged Cbfb (WT and its 
spliced isoform), 293 GP2 cells were co-transfected with the appropriate constructs. 
Two days later, the medium was aspirated and the cells were washed twice using 
cold PBS. The cell pellets were lysed in a buffer containing Tris-HCl PH 8.0 (50mM), 
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Nacl (150mM), NP40 1% and Roche Protease inhibitor  (1:25) for 60 minutes at 4oC 
with rotation. Cells were centrifuged (1400g) for 15 minutes at 4oC and the 
supernatant was collected in a new Eppendorf tube.  The lysate was incubated 
overnight with ANTI-FLAG® M2 Affinity Gel (Sigma) at 4oC with rotation. Then, the 
cells were washed three times using 0.5ml of TPBS for 5 minutes with rotation. The 
Flagged AEs were eluted from the affinity gel using SDS-PAGE sample buffer and 
loaded into gels for Western blotting. 
2.10 Western blotting 
 
1-2x106 cells were lysed using 2x SDS-PAGE sample buffer (0.5M Tris-HCl, 
Glycerol, 10% SDS and 0.5% bromophenol blue) and incubated for 5 minutes at 
95oC. 10µl of protein ladder (PageRuler TM plus Prestained protein ladder, 
Fermentas) and 20µl of each samples were loaded into 12% gradient SDS 
polyacrylamide gel (NEXT GEL TM, Amresco) and separated at 140 V for 90 minutes, 
and then blotted onto a nitrocellulose membrane (Amersham TM Hybond TM ECL) for 
1 hour at 100 V. After that, the transferred membrane was blocked using 2.5 g of 
milk dissolved in 50 ml of PBS-T with 0.1% Tween 20 (Promega) for 2 hours at room 
temperature. Then, the membrane was probed with anti-Cbfβ antibody (ab33516, 
1:500), anti-flag M2 antibody (Sigma, 1:7000) or anti-HA antibody (Covance, 
1:4000) for overnight at 4oC. The membrane was washed with PBS-T (3 times, 10 
minutes) and incubated with secondary antibody conjugated with HRP for 1 hour at 
room temperature.   The membrane was washed and the signal was detected using 
ECL detection system (Amersham TM, GE Healthcare) and developed on X-ray film 
(AmershamTM, Hyperfilm ECL) using photon imaging system.  
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2.11 Reverse transcriptase (RT) and Quantitative Reverse 
Transcriptase Polymerase Chain Reaction (qRT-PCR) 
 
Total RNA were extracted using either Macherey-Nagel (MN) or mirVana™ 
miRNA Isolation Kits according to the manufacturer’s instructions and the RNA 
concentration was measured using NanoDrop 8000 (Thermo Fisher Scientific). The 
cDNA synthesis was carried out using SuperScript III kit (Invitrgen). Briefly, for 20µl 
reaction volume: 1 μl of oligo dT (50µM), 1μl of 10 mM dNTP mix, 10pg –3μg total 
RNA and sterile water was added to get 13µl volume. Then, the mixture was 
incubated at 650C for 5 minutes followed by 1 minute incubation on ice. After that, 
7 µl of a master mix of (4 μl of 5X First-Strand Buffer, 1 μl of 1 μl 0.1 M DTT, 1 μl 
RNaseOUT™(40U/ μl), 1 μl of SuperScript™ III RT (200 units/μl) were added to each 
sample and subjected to PCR reaction using Veriti® Thermal Cycler machine 
programmed with the following conditions: 25oC for 5 minutes, 50oC for 60 
minutes,  70 oC for 15 minutes and hold at 4oC. To confirm the presence of AE or 
AE9a in the transformed or leukaemic cells, 1µl of cDNA template was amplified 
using the following PCR conditions together with the primers listed in table 2.4: 
denaturation for 45 seconds at 94oC, annealing  for 45 seconds at 58 oC, and 
extension  for 90 seconds at 72 oC (Yan, Kanbe et al. 2006).  To quantify the 
expression level of our genes of interest, real time PCR was carried out either by 
TaqMan® Fast Universal Master Mix (table 2.5) or Fast SYBR® Green Master Mix 
(table 2.6) using StepOnePlus™ Real-Time PCR System (Applied Biosystems®). 
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Table ‎2-4 Primers pairs for RT-PCR 





mGAPDH 5’- ACCACAGTCCATGCCATCAC -3’ 





Table ‎2-5 Primers pairs and probes for qRT-PCR using TaqMan 
Cbfb major  5'-CAGGAAGATGCATTAGCACAA-3' 




Reverse   






Reverse   
 
Table ‎2-6 Primers pairs for qRT-PCR using SYBR green 
   
Mouse Mpl 5’- TCACCTTGGTGACTGCTCTG-3’ Forward 
 5’-CCACAAAGCATGCCTCAGTC-3’ Reverse  
Mouse Cebpα 5’-GCAAAGCCAAGAAGTCGGTG-3’ Forward 
 5’-CACCTTCTGTTGCGTCTCCA-3’ Reverse 
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2.12 RNA Sequencing 
 
Briefly, mirVana™ miRNA Isolation Kit (life technology) was used to extract RNA 
from 1-3 x106 cells according to the manufacturer’s instructions and the quality of 
the extracted RNA was assessed using the Agilent 2100 bioanalyzer (Agilent 
Technologies). cDNA libraries were prepared using TruSeq Stranded Total RNA LT 
Sample Prep Kit (Illumina® ) and the sequencing was carried out at department of 
haematological medicine, (KCL) using HiSeq™ 2000 Sequencing System, Illumina®. 
Our RNA sequencing data was analysed by Dr. Magdalena Zarowiecki who is the 
bioinformatics head in our research group. Dr. Zarowiecki performed the following 
analysis:  
The FASTQ files were de-tagged, and the quality of the FASTQ files inspected using 
FastQC v.0.11.2. Remaining adapters were trimmed using TRIMGalore v.0.3.7. 
Reads were mapped to the Ensembl mouse genome using TopHat2 v2.0.13, reads 
filtered for quality and counted using samtools v.0.1.18 and bedtools v2.23.0-10-
g447cb97. Differential expression was determined either using DESeq2 Negative 
Binomial GLM fitting and Wald statistics. Functional enrichment analysis was 
conducted using the GSEA software, using the Molecular Signature Database c2 set 
(MSigDB), and a custom made gene sets. For the GSEA analysis, human-mouse gene 
orthologues were identified using MGI list of orthologous genes, and Ensembl 
bioMart used to transfer MGI IDs to Ensembl gene IDs. The visualization of reads 
mapping to Cbfb was done using the software Artemis.  
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2.13 FACS analysis of Transformed cells 
2.13.1 General Stain 
 
5-10 X104 cells were stained in FACS tubes with master mix of antibodies 
(PE-c-Kit, PE/Cy7-Mac-1, PerCP/cy5.5-Gr-1(Biolegend), Pacific Blue-B220, Alex 
Flour®700-CD4, APC-eFlour®780-CD8 (eBioscience), FITC-CD45.1 and APC-CD45.2 
(Biolegend) in 1:200 dilutions for 30 minutes in a dark place at 4oC. The stained cells 
were washed with SM and resuspended in 300 µL of SM with 1µg/ml of PI. Cells 
were analysed using LSRII flow cytometer (BD Bioscience).  
2.13.2 Cell Cycle Analysis using Propidium Iodide (PI) 
 
0.1-1x106 cells were washed twice with cold PBS in FACS tubes and 
centrifuged for 5 minutes at 300 g. The supernatant was aspirated and cells were 
resuspended in 200 ul of PBS and fixed by 70% cold ethanol for at least 1 hour at 
4oC. The fixed cells washed twice with cold PBS and stained with 200 ul of PI stain 
(PBS: 0.2X FBS, 40ug/ml RNase (Sigma), 40ug/ml PI (Sigma) for 30 minutes at 4oC in 




A mixture of 1 x106 of MNCs or cell lines with 2x105 rescue cells were 
resuspended into 150µl of PBS and injected (tail vein) into irradiated (1100 or 1350 
rad, 2 doses) mice. CD45.1 and CD45.2 (Biolegend) markers were used to 
distinguish donor from recipient cells. For generating a leukaemia mouse model, 
fetal liver cells or BM c-kit+ cells were harvested and plated into 6-well plates as 
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described earlier. The cultured cells were transfected with 2 ml of MigR1 AE9a viral 
suspension and subjected to the first spinoculation. 24 hours later, the media were 
aspirated leaving only 1 ml and the second spnioculation was carried out using 2 ml 
of the MigR1 AE9a viral suspension and at the end of this step 2 ml of fresh media 
were added. The cells were expanded for 48 hours and their phenotypes were 
analysed using FACS machine and then transplanted as described earlier. For in vivo 
Cre-recombinase, mice were injected with 2-5 consecutive intraperitoneal (IP) 
injections (120µL of 10mg/ml in corn oil) of tamoxifen (Sigma).  The sick animals 
routinely subjected to a comprehensive analysis as illustrated in figure 2.4.  
 
 
Figure ‎2-4 Analysis of sick mouse. 
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2.15 Tail Vein Bleeding (TVB) 
 
TVB was performed by a qualified person who got the animal license after 
passing a training course.  In this procedure, a small cut was made at the end to the 
tail and then few drops of blood were squeezed into an Eppendorf tubes pre-
coated with 0.01 M Ethylenediaminetetraacetic acid (EDTA) (Sigma). The blood 
parameters (WBC, RBC, Platelets etc.) were measured using Mythic 18 Vet coulter 
machine (Woodley Company).     
2.16 Giemsa stain 
 
A peripheral blood smear was prepared by spreading a small drop of tail 
vein or heart puncture blood on a microscopic slide and left to dry for few minutes. 
BM, spleen and liver cytospins were prepared in a Cytospin™ 4 Cytocentrifuge 
(Thermo Scientific™) and span for 5 minutes at 300 rpm. The slides were firstly stain 
with May-Grünwald stain (Sigma) for 3 minutes and then washed with water. After 
that, the washed slides were stained with diluted Giemsa stain (1:20, Sigma) for 20 
minutes and then washed with water. Finally, the slides were left to dry for several 
minutes and examined under a microscope equipped with a camera.   
2.17 Histology 
 
Spleen and liver samples were fixed in 10% formalin buffer and sent to 
histopathology department at king’s college hospital. The samples were processed 
and stained with Hematoxylin and eosin (HE) stains.  
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2.18 Statistical analysis  
 
All the statistical analyses were performed by GraphPad software using a 
two-tailed unpaired student t-test. Kaplan-Meier survival curves were also 
generated by this software and statistically analysed using a Log-rank (Mantel-Cox) 
test. 
2.19 Ethical approval  
 
All the animal works in this thesis were approved by the UK Home Office 
(Project license number 70/7867 & personal license number 70/19320). In addition, 
all the animal handling and procedures that carried out in our lab were reviewed 
and approved by the Biological Services Unit (BSU) at King’s College London. 
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3 Effect of Cbfb in Leukaemogenesis 
3.1 A Brief Introduction 
 
As mentioned earlier, AML1 and CBFB genes are among the most frequent 
targets for chromosomal translocations in acute leukaemia generating AML1-ETO 
(AE) fusion and CBFβ-SMMHC fusion, respectively.  Based on mutagenesis studies, 
our group previously created Cbfb-interaction defective AE mutants and 
demonstrated that the in vitro transformation activities of these AE mutants were 
Cbfb independent. In addition, AE transformation activity remained largely 
unchanged when the endogenous expression of CBFβ was knocked down by  
around 95% using a shRNA approach (Kwok, Zeisig et al. 2009). However, a study by 
another group using Cbfb-interaction defective AE mutants in different 
experimental settings have yielded conflicting results, in which Cbfb-interaction 
defective AE mutants failed to transform (Roudaia, Cheney et al. 2009). Thus the 
exact functional role of Cbfb in AE mediated transformation was unknown at the 
start of my PhD project.  
Definition of Cbfb requirement is important for understanding the biology of 
the disease and also for designing better cancer therapeutics, in particular when 
inhibitors targeting Cbfb/AML1 interaction are being developed for this purpose 
(Gorczynski, Grembecka et al. 2007; Cunningham, Finckbeiner et al. 2012). It is well 
recognized that it is almost impossible to generate mutations, which affect only a 
single property of a protein leaving other features untouched.  Therefore the use of 
a Cbfb conditional KO mouse model in combined with wild type AE is considered as 
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a complementary approach to the mutant studies to draw a more definitive 
conclusion. To this end, I decided to investigate the role of Cbfb in AE 
leukaemogenesis by employing different experimental strategies (in vitro and in 
vivo) and examining different potential origins of LSC (BM and fetal liver).  
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3.2 Results 
3.2.1 The impact of Cbfb deletion on the in vitro self-renewal of primary 
haematopoietic cells transformed with AEs. 
3.2.1.1 Cbfbf/f RosaYFP/WT mouse  
 
To investigate the effect of Cbfb in AEs transformation activity, I firstly used 
the Cbfbf/f RosaYFP/WT mouse model, which carried floxed alleles flanking exon 5 
of Cbfb and a Rosa-stop-YFP marker but lacking a transgenic Cre-recombinase. 
Instead of disrupting the whole Cbfb function, the advantage of this KO model is its 
generation of exon 5-deleted Cbfb splicing variant that fails to interact with AML1.  
This mouse model was in a mixed background and has already been present at the 
start of my PhD study. c-Kit + haematopoietic stem and progenitor cells were 
isolated from bone marrow of these mice and subjected to RTTA in the absence or 
presence of Hit and Run Cre (HR-cre)(Silver and Livingston 2001; Yeung, Esposito et 
al. 2010) as shown in figure 3.1 A. RTTA is an in vitro serial replating assay, in which 
only transformed cells form colonies in each round of plating whereas non-
transformed cells will exhaust their proliferative capacity after the first or second 
round of plating. As a result and similar to MAF9 controls, AE transformed cells 
yielded comparable number of 3rd and 4th round colonies in the absence or 
presence of HR Cre, suggesting that Cbfb may not be required for in vitro 
transformation mediated by AE (figure 3.1 B). However, PCR genotyping of cells 
from 3rd round colonies showed incomplete Cbfb deletion in this experimental 
approach (figure 3.1 C) as a floxed band could still be detected in the HR-Cre co-
transduced sample. To overcome this issue, YFP marker as a proxy for active Cre-
recombination was used to purify Cbfb deleted cells (figure 3.2 A, B). As a result, 
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AE9a transduced cells subjected to YFP sort either after the first or second round of 
replating showed a similar transformation potential as their YFP negative 
counterparts but with slightly reduced number of colonies (figure 3.2 C, D). 
Crucially, the YFP positive AE9a transformed cells show a complete deletion of Cbfb 
in multiple round of replating (figure 3.2E), suggesting that Cbfb may be 









Figure ‎3-1 Complete deletion of Cbfb was not achievable using HR-Cre without sorting. 
(A) A diagram shows the strategy for investigating the role of Cbfb in AE activity using c-Kit 
isolated from Cbfbf/f RosaYFP/WT mouse.  (B) A bar chart illustrates numbers of first-, 
second-, third- and fourth-round colonies of AE, AE9a, MAF9 and MSCV transduced cells in 
the presence and absence of HR-Cre. Error bars indicate mean ± SD of three independent 
experiments. (C) A representative samples show genotyping of the third round colonies of 
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Figure ‎3-2 Sorting strategy to achieve a complete deletion of Cbfb. 
(A and B) Diagrams show the sorting strategy to achieve a complete deletion of Cbfb and 
also to enrich the deleted cells (C) A bar chart illustrates numbers of third- and fourth -
round colonies of sorted AE9a transduced cells. Error bars indicate mean ± SD of two 
independent experiments. (D) Photos show colony morphology of sorted AE9a - and + YFP 
transduced cells. (E) A representative samples show genotyping of the sorted AE9a 
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3.2.1.2 Cbfbfl/fl Rosa 26 Cre ER mouse 
 
In order to reduce toxicity associated with viral Cre expression and to exert 
better control of the Cre recombinase, an improved Cbfbfl/fl Rosa26 CreER mouse 
model has been generated by crossing the existing Cbfbfl/fl mouse with a Rosa26 
Cre ER mouse. This new mouse model has been also backcrossed for 6 generations 
with C57BL/6 mice to obtain a pure C57BL/6background for future transplantation 
studies. In contrast to the previous mouse model, the activity of Cre in the Cbfbfl/fl 
Rosa26 CreER mouse can be controlled by addition of tamoxifen both in vivo and in 
vitro. To further characterize this mouse model, qPCR primers and probes were 
designed to detect the expression level of both Cbfb major and minor transcripts. 
As illustrated in figure 3.3 A, exon 4-5 and exon 4-6 were considered to design 
primers and probe that specifically detect the expression level of the major and 
minor transcripts, respectively. In vitro incubation of AE9a transformed Cbfbfl/fl 
Rosa26 Cre ER bone marrow cells with tamoxifen (25nM 4-OHT, Sigma) for 3 days 
resulted in a complete deletion of the major transcript of Cbfb as determined by 
qPCR (figure 3.3 B). Although, the deleted cells still expressed the minor transcript 
mRNA (figure 3.3 B), its expression level was lower than the major one (figure 3.3 
C). A higher concentration of 4-OHT (50nM) was required to achieve a complete 
deletion of cbfb in the MTA assay as determined by genotyping PCR on genomic 
DNA (figure 3.4 A). Also, similar results were observed at the protein level as 
demonstrated by WB (figure 3.4 B) confirming that deletion of Cbfb in this mouse 
model, and likely in the previous mouse model, as it utilized the same Cbfb 
targeting strategy, resulted in a spliced isoform lacking exon 5. To investigate the 
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properties of the spliced isoform, in particular its potential to interact with AE, both 
WT Cbfb as well as the spliced form were tagged with HA tag and co-expressed with 
Flag-tagged AEs. As expected, the WT Cbfb was able to bind both forms of AE (AE, 
AE9a) and failed to interact with mutant AE M106V carrying a point mutation that 
disrupts Cbfb binding (Kwok, Zeisig et al. 2009), whereas the Cbfb spliced form was 
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Figure ‎3-3 Quantifying the expression level of the major and minor transcripts of Cbfb. 
(A) A diagram illustrates locations of the primers and probes that used for qPCR to detect 
the expression levels of Cbfb transcripts. (B) Expression of cbfb major and minor transcript 
in WT and KO samples relative to their levels in WT assessed by RT-qPCR. (C) Expression of 
cbfb major and minor transcript in WT and KO samples relative to the expression level of 
Cbfb major transcript in WT assessed by RT-qPCR. Error bars represent mean ± SD of three 
independent experiments.  
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Figure ‎3-4 Clarifying the interaction between AEs and Cbfb. 
(A) Genotyping of c-kit+ cells isolated from Cbfbfl/fl Rosa26 CreER mouse and subjected to 
RTTA using different concentration of 4-OHT (5, 10, 25, 50nM). (B) Western blot (WB) of 
transformed primary bone morrow cells with or without 4-OHT treatment using anti Cbfb 
or anti actin antibodies (loading control). (C)Co-immunoprecipitation assay between flag-
tagged AEs and HA-tagged Cbfb constructs. Anti-flag Antibodies used for 
immunoprecipitation (IP) and anti-HA antibodies used for WB.   
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To gain better insight into the role of Cbfb in AE in vitro transformation, c-kit 
positive haematopoietic stem/progenitor cells were isolated from Cbfbfl/fl Rosa26 
CreER mice, transduced with AE, AE9a and MN1 and subjected to RTTA as described 
earlier in the absence or presence of tamoxifen (50 nM 4-OHT, Sigma). Cells were 
serially replated following either tamoxifen or the vehicle (ethanol) treatment after 
the first round of plating. Although a reduction in the numbers of colonies of the 
tamoxifen treated AE and AE9a transduced cells was observed particularly during 
the third round of plating along with modest changes on the morphology, AE 
transformation was impaired but not completely abolished as these cells were able 
to form third and fourth-round colonies (figure 3.5 A, E). PCR genotyping confirming 
a complete deletion of Cbfb in tamoxifen treated samples (figure 3.5 B) 
demonstrating the robustness of the new mouse model. In addition, the 
transformed cells do express AE as it was confirmed using RT-PCR (figure 3.5 D). In 
contrast, colony numbers of MN1 transformed cells were similar with or without 
tamoxifen treatment, suggesting that MN1 in vitro mediated transformation is Cbfb 
totally independent (figure 3.5 A). To investigate the impact of Cbfb deletion on 
maintenance of AE or MN1 transformation, transformed cells were harvested after 
the third round and subjected to 4-OHT treatment and plated for further rounds. 
The maintenance of AE transformed cells was significantly compromised upon Cbfb 
deletion as it resulted in a significant reduction of colonies compared to the control 
and loss of Cbfb had no effect on the maintenance of MN1 transformation (figure 
3.5 C).   
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To investigate the role of Cbfb in MN1 leukaemogenesis, pre-LSC MN1 cell 
lines (early transformed primary cells) for both Cbfb WT and KO were established 
after the third round of replating and then injected into sub lethal irradiated SJL 
mice. Both Pre-LSC cell lines could effectively induce leukaemia in primary 
recipients (figure 3.5 F). Interestingly, mice injected with Pre-LSC MN1-del Cbfb 
developed leukaemia faster than the non-deleted cells (figure 3.5 F). Similar results 
were also obtained when Cbfb was deleted in vivo after the transplantation (figure 
3.5 F). PCR genotyping showed that a complete Cbfb deletion was achieved in MN1 
leukaemic cells (figure 3.5 G). These data strongly suggest that MN1 
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Figure ‎3-5 AE in vitro activity was affected upon cbfb deletion but does not completely 
abolished. 
(A) A bar chart illustrates numbers of first-, second-, third- and fourth-round colonies of AE, 
AE9a, MN1 and MSCV transduced cells in the presence and absence of 4-OHT. Error bars 
indicate mean ± SD of four independent experiments. (B) Representative samples for 
genotyping of the AE transformed cells showing the deleted as well as the floxed bands of 
Cbfb. (C) A bar chart illustrates numbers of fourth- and fifth-round colonies of AE, AE9a, 
MN1 transformed cells with or without 4-OHT treatment. Error bars indicate mean ± SD of 
two independent experiments. (D) Representative samples for RT-PCR confirming the 
expression of AE9a. (E) Colony morphology of AEs transformed primary bone marrow cells 
in the 3rd round of plating with and without 4-OHT treatment using different 
magnifications. (F) Kaplan-Meier survival curve of MN1 transplanted mice with and without 
tamoxifen treatment (WT cbfb n=4, KO cbfb n=5, in vivo KO n=5).  (G) Representative 
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3.2.2 The impact of Cbfb deletion on the in vitro self-renewal of LSK, CMP and 
GMP cells transformed with AEs. 
 
In addition to investigate the role of Cbfb in AE transformation of bone 
marrow c-kit+ haematopoietic stem/progenitor cells, another aim of my study was 
to identify the identity of haematopoietic cells susceptible to AE transformation, i.e. 
the cell of origin and determine the Cbfb dependency in AE mediated 
transformation in these populations. In addition to the use of primary bone marrow 
cells carrying Cbfb floxed alleles, a complementary approach using AE mutants with 
specific mutations affecting Cbfb interaction was also employed. For the latter,  
haematopoietic stem/progenitor cells were sorted from WT mice and subjected to 
RTTA with AE full length, AE9a short form, empty vector and the AEY113A/T161A 
mutant, which carries 2 point mutations disrupting its Cbfb interaction (Roudaia, 
Cheney et al. 2009; Kwok, Zeisig et al. 2010). Briefly, mononuclear cells were 
isolated from 5 WT mice, pooled together and then subjected to lineage (lin) 
depletion. Lin- cells were collected and stained with Sca1, c-kit, CD34 and CD16/32.  
Progenitors and LSK were gated using Sca1 and c-kit markers and then CD34 
together with CD16/32 were used to differentiate between GMP and CMP within 
the progenitors’ population (figure 3.6 A)(Yeung and So 2009). To confirm the 
purity of the sorted cells, a post-sort analysis for LSK, CMP and GMP was conducted 
which showed a good purity (>91%)(figure 3.6 B). In addition to phenotypic purity 
analysis, functional CFU assay was performed using the sorted cells and it showed 
that, as expected, LSK formed mainly GM colonies and the percentage of G and M 
colonies was higher with GMP comparing to CMP (figure 3.6 C).   
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Moreover, at the molecular level, we used known markers to further validate the 
purity of the sorted cells such Mpl and Cebpa that were shown to be highly 
expressed in LSK and GMP, respectively (Zhang, Iwasaki-Arai et al. 2004; Chou and 
Mulloy 2011) (figure 3.6 D, E). Interestingly, our data also demonstrated that 
expression of Cbfb is high in HSCs and then decreases through haematopoietic 
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    Figure ‎3-6 Sorting of murine haematopoietic stem/progenitor cells. 
(A) Our gating strategy for LSK and progenitors in which lin- cells were gated using Sca1 and 
c-kit markers, GMP and CMP were gated from the progenitors using CD34 and CD16/32 
markers. (B) Post sort analysis for LSK, GMP and CMP showing the percentage of their 
purity. (C) A bar chart illustrates CFU assay of LSK, GMP and CMP cells and the percentage 
of GM-G-M-GEMM-BFU-E colonies that were able to form. (D-F) A bar chart shows 
expression of Mpl, Cebpa and Cbfb in LSK, CMP, and GMP isolated from WT mice. Error 
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Results from the RTTA demonstrated that AE, AE9a as well as the Cbfb-
interaction defective AE mutant Y113A/T161A albeit with reduced numbers of 
colonies compared to the controls were all able to transform all tested sorted 
haematopoietic cell populations isolated either from WT (figure 3.7 A) or Cbfbfl/fl 
Rosa26 CreER mice (figure 3.7 B-D). Collectively, these data suggest that the two 
forms of AE are able to transform multiple distinct haematopoietic stem/progenitor 
cell populations and that disrupting the binding between AE and Cbfb either by 
using a mutant AE (Y113A/T161A) or by deleting Cbfb using 4-OHT (figure 3.7 E) 
does compromise but not completely impair the in vitro AE-mediated 
transformation suggesting that Cbfb might have a moderate effect on AE-mediated 
transformation of stem/progenitor cells.   
An AE9a transformed cell line from Cbfbfl/fl Rosa26 CreER LSK was 
established after the RTTA and transplanted into mice to test if a novel AE 
leukaemia model could be created. This cell line expressed Mac1, Gr1 and was 
CD45.2 positive (figure 3.7 F) and was injected into two groups of irradiated mice; 
one of them was treated with tamoxifen a week later to delete Cbfb, the other 
served as control.  Although mice were followed up for almost one year, neither 
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Figure ‎3-7 Deletion of Cbfb resulted in a reduced numbers of third -round colonies of AE 
transformed LSK, CMP and GMP. 
(A) Numbers of third-round colonies of sorted distinct haematopoietic cell populations 
(LSK, CMP, and GMP) isolated from WT and transduced by AE, AE9a and AEY113A/T161A 
mutant. (B-D) Numbers of third-round colonies of sorted distinct haematopoietic cell 
populations (LSK, CMP, and GMP) isolated from Cbfbfl/fl Rosa26 CreER mice and 
transduced by AE, AE9a and MN1 with and without 4-OHT treatment. Error bars indicate 
mean ± SD of two independent experiments.  (E) Representative samples for genotyping of 
the third round of the AE9a transformed LSK, CMP and GMP showing the deleted as well as 
the floxed bands of Cbfb. (F) Flow cytometric analysis showing the phenotype of pre-LSC 
LSK AE9a Cbfb WT. (G) Kaplan-Meier survival curves of mice transplanted with pre-LSC LSK 
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3.2.3 Establishing an in vivo model to further clarify the role of Cbfb in AE 
leukemogenesis. 
 
It is well known that the full length AE alone is not able to induce leukaemia 
in murine models and other mutations in e.g. KIT or RAS cooperating with AE are 
needed to establish AE leukaemia in murine models (Wang, Zhao et al. 2011; Zhao, 
Zhang et al. 2014). On the hand, the short form of AE (AE9a) which was detected in 
AML patients can efficiently induce leukaemia in murine models only when fetal 
liver cells are used (Yan, Kanbe et al. 2006). Therefore, we used the fetal liver 
approach together with AE9a to establish our AE leukaemia model with conditional 
Cbfb floxed alleles. To first characterize their self-renewal property in vitro, fetal 
liver cells (E11-E15.5) were isolated from Cbfbfl/fl Rosa26 CreER embryos and 
subjected to RTTA assay with or without 4-OHT treatments using MigR1AE9a 
construct, which carries a GFP marker. As a result, enhanced self-renewal of fetal 
liver cells transformed with AE9a was observed as the transformed cells harbouring 
Cbfb floxed alleles were able to form colonies for multiple rounds of replating 
(figure 3.8 A). In contrast, deletion of cbfb resulted in a significant reduction in AE9a 
mediated transformation ability as the deleted cells started to lose their ability to 
form colonies comparing to the Cbfb floxed controls (figure 3.8 A). Moreover, a cell 
line was created after the third round of plating and subjected to an in vitro 4-OHT 
treatment (20nM) for 72 hours which was sufficient to achieve a complete deletion 
of Cbfb (figure 3.8 B). The Cbfb-deleted cells lost their ability to proliferate, started 
to attach to the flask and the cytospin preparations showed that most of them 
differentiated in mature myeloid cells such as macrophages (figure 3.8 C).  
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To test the in vivo leukaemia properties, the established cell line was 
injected into irradiated mice and the transplanted animals were divided into two 
groups; one group received tamoxifen treatment to induce the deletion of Cbfb one 
week after transplantation, the other served as control.  Unfortunately, neither the 
control group nor the treated one develop leukaemia and this experiment was 
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Figure ‎3-8 Self-renewal of fetal liver cells transformed with AE9a was severely 
compromised upon Cbfb deletion. 
(A) A bar chart illustrates numbers of third-, fourth-, fifth- and sixth-round colonies of AE9a 
with or without 4-OHT treatment. Error bars indicate mean ± SD of two independent 
experiments. (B) Representative samples for genotyping of the AE9a transformed cells 
showing the deleted as well as the floxed bands of Cbfb. (C) Cytospin stains for AE9a 
transformed cells with and without 4-OHT treatment. (D) Kaplan-Meier survival curves of 
mice transplanted with AE9a cell line with and without tamoxifen treatment (WT cbfb n=5, 
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 In parallel, another approach was used in which fetal liver cells (E15.5) were 
isolated from Cbfbfl/fl Rosa26 CreER embryos and transduced with MigR1 AE9a and 
transplanted into mice 2 days after retroviral transdcution. The phonotypes of the 
transduced cells were analysed before transplantation into irradiated mice. One 
week after transplantation mice were split in to two groups with  one group 
receiving tamoxifen treatment and the other serving as control (figure 3.9 A). 
Before transplantation, around 10-12% of live cells expressed GFP, are expressing 










Figure ‎3-9 Our in vivo approach to establish the leukaemia model.    
(A) Schematic diagram illustrating the in vivo leukaemogenic experiment. (B) Flow 
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3.2.3.1 AE9a leukemogenesis is dependent of Cbfb 
The MigR1 AE9a transplanted mice (figure 3.9 A) were monitored for signs 
of sickness such as loss of weight, weakness and difficulty of breathing. 
Interestingly, MigR1 AE9a cbfbf/f mice got sick whereas the KO group remains 
healthy (figure 3.10 A). The sick mice were anaemic, showed high white blood cell 
(WBC) and had  pale femurs, enlarged spleens as well as enlarged livers (table 3.1, 
figure 3.10 B). Flow cytometric analysis of cells harvested from BM, spleen and liver 
of the sick mice showed high percentage of GFP+ cells which were c-Kit+ with no 
expression of lineage markers such as CD11b and Gr-1 (figure 3.10 C). Consistent 
with previous report showing that CD45 is a downstream target repressed by AE (Lo 
and Peterson 2013), GFP+ cells didn’t express CD45.2. Moreover, the expression of 
AE9a in GFP+ cells isolated from bone marrow, spleen and liver expressed AE9a was 
confirmed by RT-PCR (figure 3.10D). In addition, histological hematoxylin/eosin (HE) 
staining showed infiltration of the blast cells in the spleens and livers comparing to 
the WT (figure 3.10 E). Moreover, high numbers of blast cells were observed in the 
peripheral blood (PB), BM, spleen and liver (figure 3.10 F). Together these data not 
only show that I successfully generated a murine in vivo AE9a leukaemia model with 
Cbfb floxed alleles, but that Cbfb is absolutely required for AE9a mediated 
leukaemia in this experimental system. 
 Table ‎3-1 Features of sick mice injected with MigR1 AE9a fetal liver transformed cells. 
 WT  MigR1 AE9a  
WBC (109/L)* 9.1 ± 3.9 45.2 ± 30.6 
RBC (1012/L)* 8.5 ± 0.77 2.3 ± 0.9 
HGB (g/dL)* 11.1 ± 0.82 4.05 ± 1.5 
PLT (109/L)* 687.4 ± 306.5 132.4 ± 123.7 
Spleen weight (g)* 0.086 ± 0.014 0.64 ± 0.12 
Liver weight (g)* 1.2 ± 0.28 2.5 ± 0.69 
* Values presented as mean ±SD 
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Figure ‎3-10 AE9a leukemogenesis is dependent of Cbfb.  
(A) Kaplan-Meier survival curve of AE9a transplanted with and without tamoxifen 
treatment (WT cbfb n=12, KO cbfb n=12) (B) Representative photos show the sizes of 
spleen and liver of healthy WT mice comparing to MigR1 AE9a sick mice. (C) Representative 
flow cytometry profiles of cells harvested from the BM, spleen and liver of the sick mice. 
(D) Representative RT-PCR test showing the expression of AE9a. (E) Representative photos 
show the HE stain of spleen and liver of healthy WT mice comparing to MigR1 AE9a sick 
mice. (F) Representative photos show the Giemsa stain of cells harvested from PB, BM, 
spleen and liver of the MigR1 AE9a sick mice. 
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Next, the impact of Cbfb deletion on maintaining AE9a leukaemia was 
investigated. To this end, leukaemia cells from primary leukemic mice were 
harvested and transplanted into two groups of irradiated mice. One group was 
injected with tamoxifen one week after transplantation to delete Cbfb in vivo, the 
other group served as control.  In contrast to mice transplanted with AE9a Cbfb 
floxed allele leukaemic cells which got sick rapidly with a median survival of 23 
days, the Cbfb  KO cells were significantly compromised to induce leukaemia in the 
transplanted mice (figure 3.11 A). Sick mice were anaemic with massive spleens and 
livers suggesting the infiltration of blasts cells in these organs which was confirmed 
by HE and Giemsa stains (figure 3.11 B, E, and F). Moreover, these cells expressed 
AE9a and their phenotypes were identical to the transplanted one as they only 













 Chapter 3 Cbfb in leukaemogenesis 























Figure ‎3-11 The maintenance of AE9a leukemogenesis is dependent of Cbfb. 
 (A) Kaplan-Meier survival curve of LSCs AE9a transplanted with and without tamoxifen 
treatment (WT cbfb n=8, KO cbfb n=8) (B) Representative photos show the sizes of spleen 
and liver of AE9a sick mice. (C) Representative flow cytometry profiles of cells harvested 
from the BM, spleen and liver of the sick mice. (D) RT-PCR test showing the expression of 
AE9a. (E) Representative photos show the HE stain of spleen and liver of healthy WT mice 
comparing to AE9a sick mice. (F) Representative photos show the Giemsa stain of cells 
harvested from PB, BM, spleen and liver of the AE9a sick mice. 
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3.2.3.2 Expanding of AE9a leukaemic cells  
 
 Given that fetal liver AE9a Cbfb KO cells were severely compromised in their 
in vitro growth and failed to induce leukaemia, I tried to further characterize the 
fetal liver AE9a Cbfb floxed allele leukaemic cells in the absence or presence of TAM 
treatment. Several attempts to expand these cells in vitro using RPMI medium 
supplemented with 10ng/ml IL3, 10ng/ml IL6, 20ng/ml SCF, 15% FBS and 1% 
Pen/Strep failed. To overcome this issue, we transplanted leukaemic cells isolated 
from our primary leukaemia mouse into two groups of irradiated mice (figure 3.12). 
A week later, some animals were sacrificed to examine the homing property while 
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 Our data showed that the percentage of the leukemic cells that were able 
to home inside the BM after one week was around 10 % (figure 3.13 A) . 24 h after 
the third tam injections, the transplanted cells were harvested from the BM of both 
treated and control groups.  They were then subjected to GFP sort for further 
studies such as genotyping, FACS and cell cycle analysis. The GFP percentage of the 
leukemic cells from the Cbfb KO group was significantly reduced comparing to the 
Cbfb floxed control (figure 3.13 B and C). In addition, the percentage of cells 
expressing c-kithigh dropped dramatically after Cbfb KO suggesting a change in the 
phenotype of these cells (figure 3.13 D and E). Cell cycle analysis revealed that the 
KO cells were arrested at G0/G1 stage and failed to enter S or G2/M stages 
compared to the control cells (figure 3.13 F). Consistently, the KO cells were unable 
to induce leukaemia into secondary recipient whereas the Cbfb floxed controls 
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Figure ‎3-13 Deletion of Cbfb reduced the expansion of AE9a leukaemic cells. 
(A) A bar chart illustrates the percentage of leukaemic cells (GFP+) that were able to home 
in the BM of secondary recipients and harvested one week post transplantation before 
tamoxifen treatment. (B) Representative samples for genotyping of the AE9a leukemic cells 
with and without TAM treatment. (C) A bar chart shows the percentage of AE9a leukaemic 
cells (GFP+) isolated from the Cbfbf/f and KO groups after 3 injections of tamoxifen. (D) A 
bar chart shows the percentage of AE9a leukaemic cells (sorted GFP+) that expressed c-
kithigh isolated from the Cbfbf/f and KO. (E)  Flow cytometry profiles shows the phenotypes 
of AE9a leukaemic cells (sorted GFP+) isolated from the Cbfbf/f and KO groups. (F) A bar 
chart shows the cell cycle profiles of AE9a leukaemic cells (GFP+) cells Cbfbf/f and KO cells. 
(G) Kaplan-Meier survival curves of AE9a leukaemic cells (GFP+) transplanted mice with and 
without tamoxifen treatment (Cbfbf/f n=4, KO n=4). AE9a leukaemic cells (GFP+) harvested 
from primary leukemic mice (MigR1 AE9a Cbfbf/fRosa 26 Cre ER) in this figure are labelled 
as Cbfb f/f, whereas the tamoxifen treated one are labelled as KO. Error bars indicate data 
presented as mean ± SD.  
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3.2.3.3 Frequency of AE9a leukaemia initiating cells   
 
Limiting dilution assays (LDAs) were performed to assess the impact of Cbfb 
deletion on the frequency of AE9a leukaemia initiating cells. Serially increasing 
numbers of the leukemic cells (1000 (n=3), 5000 (n=3), 10000 (n=4), 50000 (n=4)) 
were injected into irradiated mice without TAM treatment. To quantify the LSCs in 
the Cbfb KO group, 2 cell doses (0.5x106 (n=4) and 4x106(n=4) were transplanted 
and subjected to TAM treatment in a week later (4 injections). As a result, all mice 
injected with 50000 LSCs-AE9a Cbfb floxed allele came down whereas 2 out of 4 
from the 10000 cell group got sick. Up-to-now neither 1000 nor 5000 LSCs were 
able to induce leukaemia (figure 3.14 A and C). Although higher dose of cells 
(0.5x106 and 4x106) were used for the KO group, neither of them were able to 
induce leukaemia (figure 3.14 B and D). Therefore, the estimated frequency of 
leukaemia initiating cells was calculated using ELDA (Extreme Limiting Dilution 
Analysis) (Hu and Smyth 2009) and for the WT group it was found as 1/17468 and 
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Figure ‎3-14 Deletion of Cbfb affected the frequency of the AE9a leukaemia initiating cells. 
(A and B) Kaplan-Meier survival curves of mice transplanted with different numbers of LSCs 
(A: WT group: 1000 (n=3), 5000 (n=3), 10000 (n=4), 50000 (n=4), B: KO group: (0.5x106 
(n=4) and 4x106(n=4).  (C and D) LDAs showed the frequencies of leukaemia initiating cells 
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3.2.3.4 Establishing AE9a leukaemia model using c-Kit + BM cells. 
 
Toward the end of my PhD, I decided to test the ability of AE9a fusion to generate a 
leukaemia model using BM cells. To this end, c-kit+ cells were isolated from the BM 
of Cbfbf/f Rosa 26 Cre ER mice were transduced with MigR1 AE9a and then 
subjected to a direct injection into two groups of irradiated mice without any in 
vitro replating assay. A week later, one group was treated with tamoxifen to induce 














Figure ‎3-15 Our in vivo approach for establishing a leukaemia model using BM c-Kit + cells. 
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  As a result, two out of five mice from the control group got sick whereas 
the KO group remains healthy (figure 3.16 A). Interestingly, the disease latency was 
longer than AE9a transformed cells derived from fetal liver.  To further define the 
role of Cbfb in disease maintenance, spleen cells were harvested from the sick 
mouse and subjected to secondary transplant into two groups of irradiated animals.   
One of them was then treated with TAM a week after transplantation.  All the 
control mice from the untreated group came down within a median survival of 28 
days, whereas the Cbfb KO group remained healthy even after 2 months (figure 
3.16 B). The phenotypes of the leukaemic cells from the primary or the secondary 
transplants were identical to the fetal liver cells, which expressed c-Kit but not Mac-
1 or Gr-1 (figure 3.16 C and D).    
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Figure ‎3-16 BM AE9a leukemogenesis is dependent of Cbfb. 
 (A) Kaplan-Meier survival curve of AE9a primary transplanted mice with and without 
tamoxifen treatment (WT cbfb n=5, KO cbfb n=5) (B) Kaplan-Meier survival curve of AE9a 
secondary transplanted mice with and without tamoxifen treatment (WT cbfb n=9, KO cbfb 
n=9) (C and D) Representative flow cytometry profiles of leukaemic cells harvested from 
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3.2.4 Preliminary RNA sequencing data showed that some of AE9a target genes 
were dysregulated upon Cbfb deletion.  
 
To gain insights into the underlying mechanisms and identify key 
downstream targets of Cbfb responsible for the phenotypes, RNA sequencing was 
carried out using AE9a in vitro transformed c-kit+ BM cells.  As shown in table 3.2, 
two biological replicates of AE9a transformed cells (3rd round of replating from 
figure 3.5 A) carrying Cbfb f/f alleles were treated with TAM during the 2nd round of 
replating to induce Cbfb deletion.  RNA from these cells with or without TAM 
treatment were prepared for RNA sequencing.  The successful deletion of Cbfb was 
confirmed by both qPCR (figure 3.17 A) and the RNA sequencing showing their 
specific depletion of exon 5 (figure 3.17 B). The PCA plot of the data demonstrated 
that 55% of the variance segregated with the KO (PC1), whereas 36% of the 
variance segregated according to the experiment (PC2) (figure 3.18 A). As shown by 
the MA plot and the heatmap, number of genes were significantly dysregulated (P-
value <0.05) as a result of Cbfb deletion (figure 3.18 B and C), in which 455 genes 
were down-regulated (list 1) and 340 genes were upregulated (list 2) (appendix 
table A1 and A2). 






+ indicates 4-OHT treatment (50nM only during the second round)   
 
Sample Description  
1 AE9a in Cbfb flox background (Exp36-4 3
rd
 round) 
2 AE9a in Cbfb KO background (Exp36-4+ 3
rd
 round ) 
3 AE9a in Cbfb flox background (Exp37-6 3
rd
 round ) 
4 AE9a in Cbfb KO background (Exp37-6+ 3
rd
 round) 
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Figure ‎3-17 The KO samples lost the expression of Cbfb major transcript. 
 (A) Expression of cbfb major transcript of AE9a Cbfb flox and AE9a Cbfb KO samples. (B) A 
diagram illustrates the deletion of exon 5 in the KO samples (blue and green colours) 
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Figure ‎3-18 Deletion of Cbfb resulted in dysregulation of some genes in AE9a transformed 
cells. 
(A) PCA plot in which PC1 explains 55% of variance and segregates with Cbfb KO, whereas 
PC2 explains 36% of variance and segregates according to experiment. (B) MA plot showing 
significantly differentially expressed genes (red) and all other genes (black). (C) Heatmap 
the significantly differentially expressed genes.  
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Recently, murine AE9a leukaemia microarray analysis showed that around 
1050 genes were dysregulated by AE9a (Lo and Peterson 2013). This will give us an 
opportunity to identify common downstream targets between AE9a and Cbfb.  
Therefore, these genes were compared with our Cbfb regulated gene lists (list 1 and 
list 2). As a result, we identified 79 commonly regulated genes including 44 down- 
and 35 up-regulated genes, respectively (figure 3.19 and appendix table A3 labelled 














Figure ‎3-19 Venn diagram illustrates the overlap between AE9a dysregulated genes in Lo's 
study with our List 1 and List 2. 
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In addition, Lo and colleges performed cross compression between the gene 
expression and ChIP-Chip data where they were able to identify some potential 
AE9a direct downstream targets (Lo and Peterson 2013). Interestingly, comparing 
list3 with these targets showed overlap of 12 genes (figure 3.20 and table 3.3 List 
5), in which 7 of them were contra regulated. For instance, Alox5, Erol1 and Ets1 
were upregulated by AE9a but their expressions were downregulated by Cbfb 
deletion. Similar comparison was carried out for list 4 and 5 genes were overlapped 
and 3 of them were contra regulated after Cbfb ablation (figure 3.20 and table 3.3 
List 6). However, future validation experiments are required to investigate if these 
genes represent potential targets or not. In addition, the current data will be 
compared with another set of AE9a data which were generated in our lab using 











Figure ‎3-20 Venn diagram illustrates the overlap between AE9a targets in Lo's study with 
List 3 and List 4. 
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Table ‎3-3 Name of overlapped genes between AE9a targets, list 3 and list 4. 
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In my initial experiments, I used c-Kit+ cells from the Cbfbf/fRosa26YFP/WT 
mouse (mixed background) and subjecting them to RTTA with AE in the presence or 
absence of HR-Cre. Although a complete deletion in the bulk population was not 
achieved in this model, it was clear that the Cbfb deleted AE transduced cells 
proliferated and contributed to the observed transformation phenotypes. To 
overcome the issue of mixed populations (Cbfb deleted and non-deleted cells), I 
took the advantage of having a YFP marker as a proxy for Cre-recombination to sort 
the AE transduced YFP+ and YFP– cells. Consistent with my previous results as well 
as published results from our group (Kwok, Zeisig et al. 2009), I was able to show 
that AE still transformed c-Kit+ cells in vitro after deletion of Cbfb.  At the same 
time, I started to generate an improved mouse line, Cbfbfl/fl Rosa 26 Cre ER mouse, 
which possess a tamoxifen inducible Cre (Cre ER), which requires only addition of 
tamoxifen for Cre activation.  
As expected, I showed that the Cbfb spliced isoform without exon 5 was 
unable to bind neither to the full length AE nor the short form AE9a. The results 
attest the usefulness of our model to specifically investigate the role of Cbfb 
interaction in AE mediated transformation. After optimizing the tamoxifen 
treatment conditions, I used in vitro transformation assay (RTTA) with c-Kit+ BM 
cells and showed that Cbfb deleted AE transformed cells formed reduced number 
of 3rd round colonies than untreated controls. However, these cells were still able to 
continue forming colonies for subsequent rounds of replating, suggesting that loss 
of Cbfb does not abolish AE mediated in vitro transformation of adult c-kit+ BM 
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cells. These findings are also highly concordant with our groups previous study 
which reported a slight reduction of the 3rd round colonies of AE (Y113A/T161A) 
mutant transformed cells, without a significant overall negative impacts on their in 
vitro transformation (Kwok, Zeisig et al. 2010).  
To gain further insight into the role of Cbfb in AE-mediated transformation 
different haematopoietic populations such as LSKs, GMPs and CMPs, I was able to 
show that AE, AE9a and AE (Y113A/T161A) mutant were able to transform LSKs, 
GMPs and CMPs.  Similarly, deletion of Cbfb resulted in a reduced number of 
colonies but did not completely abolish AE activity, suggesting that loss of Cbfb 
might only have a moderate impact on AE in vitro replating ability. Moreover, I also 
identified multiple haematopoietic populations such as LSK, CMP and CMP as 
potential cell of origins for AE mediated transformation. Although AE could 
competently transform all these populations in vitro, further in vivo studies are 
needed to confirm the cell of origin for AE mediated leukaemia. However, AE in vivo 
leukaemia models so far can only be achieved with an addition of secondary 
mutations such as RAS, TEL-PDGFR and KIT (Grisolano, O'Neal et al. 2003; Wang, 
Zhao et al. 2011; Zhao, Zhang et al. 2014). If AE models with secondary mutations 
are employed, the impact of the second mutation must be carefully assessed to 
allow definitive conclusion about the cell of origin as well as the impact of Cbfb in 
AE mediated in vivo leukaemia.  
In contrast to my data obtained using adult BM cells, AE9a-mediated in vitro 
self-renewal of fetal liver cells was severely compromised upon Cbfb deletion and 
these cells started to differentiate comparing to the floxed controls, strongly 
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suggesting an important role of Cbfb in maintaining the self-renewal and growth of 
these cells. In contrast to models using adult BM cells, AE9a alone is sufficient to 
transform fetal liver cells and induce AML in vivo (Yan, Kanbe et al. 2006; Lo and 
Peterson 2013). Therefore I adopted this approach to establish an AE9a leukaemia 
model, which allows conditional deletion of Cbfb. My data clearly demonstrated 
that Cbfb is essential for initiation of AE9a leukaemia in vivo as the KO cells failed to 
induce the disease. Moreover, the maintenance of AE leukaemia was also Cbfb 
dependent, further highlighting the importance of Cbfb in AE9a leukaemogenesis 
from fetal liver cells. The findings in the fetal liver are also in stark contrast to the in 
vitro results obtained in adult BM cells, where loss of Cbfb has minimal impact on 
AE mediated transformation. While this highlights the critical impact the choice of 
experimental system might have, it is not clear which experimental system actually 
is more relevant to the human disease as cell-of-origin for human AE leukaemia has 
not been identified. In general, the most stringent experimental settings to study 
leukemogenesis are in vivo models that induce leukaemia whereas in vitro assays 
may only act as surrogates. The development of alternative in vivo leukaemia 
models in which adult BM cells are transformed by AE alone may represent new 
opportunities and allow comparison to existing fetal liver model, which may help to 
define their relevance with respect to the human disease.  
The phenotypes of the leukaemic cells of the fetal liver model in this study 
were identical to the ones reported in previous studies as they expressed only c-kit 
but not Mac1/Gr-1 and CD45 was downregulated in these cells (Lo and Peterson 
2013). It has been shown that all haematopoietic cells express high level of CD45 
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which plays a fundamental role in B and T cells antigen receptor signalling 
(Penninger, Irie-Sasaki et al. 2001). In addition, CD45 has been found to be 
negatively regulating JAK/STAT signalling pathway (Irie-Sasaki, Sasaki et al. 2001) 
and this pathway was activated in AE9a leukaemic cells (Lo and Peterson 2013). 
Consistently, CD45 is down-regulated also by AE full length in patient samples as 
t(8;21) patients had more than 90 % reduction in their CD45 mRNA (Lo and 
Peterson 2013). Moreover, coexpression of AE9a with CD45.1 resulted in 
attenuated JAK/STAT pathway and also delayed the onset of the disease (Lo and 
Peterson 2013). These data clearly revealed the importance of CD45 
downregulation in AE9a leukaemogenesis. Our in vitro data showed that CD45 
downregulation was not achieved neither in the AE9a BM cell line nor the fetal liver 
one. Also, these cell lines lacked the expression of c-kit and this might explain why 
these cells failed to induce leukaemia as it seems external signals from the 
microenvironment might be irreversibly missing in the in vitro culture. Further 
experiments are definitely required to gain more insight into the role of CD45, c-Kit 
Jak-Stat5 and the microenvironment in AE mediated in vivo leukaemogenesis. 
To develop the alternative in vivo AE leukaemia model using adult BM and 
AE9a alone, I employed a direct injection instead of in vitro repalting strategy. 
Interestingly, 2 out of 5 mice developed leukaemia with a similar phenotype 
compared to that obtained using the fetal liver model, i.e. lack of CD45 expression 
and high c-Kit expression, although the latency was longer and the penetrance 
reduced. This mouse model was immediately used to investigate the role of Cbfb in 
AE9a leuakemogenesis in BM. Similar to the fetal liver model, the BM AE9a 
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leuakemogenesis was Cbfb dependent and the phenotypes of these cells were 
identical to the fetal liver cells, strongly suggesting that Cbfb is absolutely required 
for AE9a mediated leukemogenesis also in BM leukaemia model. For the first time 
we have shown that 2 different AE9a in vivo models using different starting cell 
populations without secondary mutations are dependent on Cbfb.  This result is 
also consistent with the findings of Roudaia using AE with secondary mutation in 
adult BM cells (Roudaia, Cheney et al. 2009). I conclude that AE transformation in 
vitro is less stringent than AE transformation in vivo, which may explain the 
different requirement of Cbfb in adult BM in vitro and in vivo. Surprisingly, AE9a 
fetal liver cells show consistent results with respect to their Cbfb dependence but 
the reasons are currently unclear. Together, my results demonstrate that AE9a in 
vivo mediated transformation is critically dependent on Cbfb in different model 
systems.  
In stark contrast, in vitro transformation activity of MN1 and its in vivo 
leukaemogenesis is completely Cbfb independent. Interestingly, deletion of Cbfb 
might indeed accelerate MN1-mediated leukaemogensis. It has been shown that 
leukaemogenesis of CBFB-SMMHC was accelerated after disrupting its binding with 
RUNX1 through deletion of the high affinity binding domain (HABD) (Kamikubo, 
Zhao et al. 2010). Intriguingly, MN1 was also upregulated in these leukaemic cells, 
and have been shown to collaborate with CBFB-SMMHC for leukaemia induction 
(Kamikubo, Zhao et al. 2010). It is tempting to speculate that selective disruption of 
Cbfb-Runx1 interaction may indeed promote leukaemogenesis in certain 
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circumstances, although further experiments are clearly required to test this 
hypothesis.    
By analysing RNA sequencing data generated using AE9a in vitro 
transformed cells, we identified only few hundred genes dysregulated by Cbfb 
ablation.  There might be several factors responsible for this. For instance, PCA plot 
showed that 36% of variance was due to some differences between the two 
experiments which were carried out to produce biological replicates. However, I 
decided to compare these data with some known AE9a targets (Lo and Peterson 
2013). It is also worth to mention this comparison is not a perfect one due to the 
differences in the experimental settings and the source of cells. I found some genes 
that were contra regulated between the two studies - Alox5 is one of them.  Alox5 
was upregulated by AE9a but ablation of Cbfb downregulates its expression. It has 
been demonstrated that the induction of chronic myeloid leukaemia by BCR-ABL 
required Alox5 and its inhibition delayed the onset of the disease (Chen, Hu et al. 
2009). Although in vitro activity of AE9a was reduced after Alox5 ablation, AE9a in 
vivo leukaemogeneis was not affected (DeKelver, Lewin et al. 2013), suggesting that 
the in vivo leukaemogenic activity might not be fully reflected by the in vitro 
transformation assays.  Nevertheless, identification of Alox5 as Cbfb target in AE 
leukaemia attests the usefulness of our model for discovering key Cbfb targets.  
Future RNA-seq analysis in combined with Cbfb ChIP-seq study will provide 
important insights into the underlying mechanisms.  
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4 Effect of Cbfb in normal haematopoiesis 
4.1 A Brief Introduction  
 
As mentioned earlier, core binding factors play a pivotal role in 
haematopoiesis through regulating different haematopoietic genes such as GM-
CSF, IL3 and T-cell antigen receptor (Shoemaker, Hromas et al. 1990; Redondo, 
Pfohl et al. 1992; Takahashi, Satake et al. 1995). Moreover, knock-out studies have 
shown that the two genes are essential for definitive haematopoiesis and mice 
lacking these genes died at E12.5 with very similar phenotypes, suggesting the 
importance and collaborative nature of these two genes for normal 
haematopoiesis. The impact of Cbfb deletion on the development of normal adult 
HSCs was poorly understood at the beginning of my PhD.  
Recently, Ouguro et al have demonstrated that LSK population can be 
subdivided into four main fractions based on their expression of SLAM markers 
CD150 and CD48: HSCs are CD150+CD48-LSK; MPPs are CD150-CD48-LSK, HPC-1 
CD150-CD48+LSK and HPC-2 CD150+CD48+LSK. In addition, using another two 
SLAM markers CD229 and CD244 they were able to subdivide HSCs into two 
fractions called HSC-1 (CD150+CD48-CD229-/lowCD244-LSK) ,HSC-2 (CD150+CD48-
CD229+CD244-LSK) and MPPS into three fractions called MPP1 (CD150-CD48-
/lowCD229-/lowCD244-LSK), MPP2 (CD150-CD48-/lowCD229+CD244-LSK) and 
MPP3 (CD150-CD48-/lowCD229+CD244+LSK) (Oguro, Ding et al. 2013). The cell 
cycle analysis of these population using Ki-67 and PI in Ouguro’s study has 
demonstrated that higher that 90% of HSC-1, HSC-2, MPP-1 and MPP-2 were in G0, 
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but MPP-2 had fewer percentage comparing to them. Moreover, the most actively 
cycling cells in LSK were HPC-1 and HPC-2 which also incorporated more 5-bromo-
deoxyuridine (Brdu) satin (Oguro, Ding et al. 2013). Furthermore, reconstitution 
experiments have suggested that HPC-1 cells are a heterogeneous population of 
restricted progenitors that contains early lymphoid progenitors and some cells that 
can give a transient reconstitution to myeloerythroid lineages. Whereas, most of 
the HPC-2 recipient mice were transiently reconstituted with very low level of 
erythrocytes and platelets and only few mice had myeloid and B cells suggesting 
that HPC-2 cells contain heterogeneous restricted progenitor with very limited 
reconstitution ability in vivo (Oguro, Ding et al. 2013).    
I decided to take the advantage of having our conditional knockout Cbfbfl/fl 
Rosa 26 Cre ER mouse model and using SLAM markers (CD150 and CD48) to shed 
light onto this issue. Three different experimental strategies were designed to 
address the cell autonomous versus non-cell autonomous role of Cbfb in normal 
haematopoietic development. Firstly, Cbfb was ablated in the whole animal simply 
by treating them with tamoxifen. Secondly, Cbfb was only ablated from the 
haematopoietic cells after their transplantation into WT mice. Finally, Cbfb was 
targeted in the microenvironment by transplantation of WT haematopoietic cells 
into Cbfb-deleted animals.  Then the haematopoietic systems of these animals were 
analysed at different time points to report any abnormality. 
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4.2 Results  
4.2.1 Conditionally deleted Cbfb mice show perturbations in haematopoietic 
stem/progenitor cells 
 
Cbfb was firstly deleted in the whole animal using the new Cbfbfl/fl Rosa 26 
Cre ER mouse model. Two groups of mice (Cbfbfl/fl Rosa 26 Cre ER and cbfbfl/fl) 
were treated with tamoxifen (100µl of 10mg/ml) for four consecutive days.  They 
were then subjected to detailed haematopoietic analysis four, eight and twelve 
weeks after tamoxifen administration.  The distribution of HSC and early 
progenitors in bone marrow were analysed using classical LSK and SLAM family 
markers (CD150 and CD48)(Yeung and So 2009; Oguro, Ding et al. 2013).  After four 
weeks, Cbfb KO mice had a significant increase in the LSK (Lin-Sca1+c-Kit+) 
population and further analysis of this population revealed severe reductions in 
CD150+CD48- (HSC), CD150-CD48- (MPP: Multipotent progenitor) but a significant 
increase in CD150-CD48+ (HPC-1: Haematopoietic progenitor cell-1) and 
CD150+CD48+ (HPC-2: Haematopoietic progenitor cell-2) populations. Moreover, 
CMP and GMP of these mice were also reduced whereas no significant difference in 
the CLP and MEP populations were observed comparing to the control floxed mice 
(figure 4.1 A). PCR genotyping confirmed a completed Cbfb deletion in different 
haematopoietic organs such bone marrow, spleen, liver and thymus of the treated 
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Figure ‎4-1 Deletion of Cbfb in the whole animal resulted in stem and progenitors defect. 
(A) Percentage of LSK and progenitors of the analysed mice Flox: Cbfβfl/fl , KO: Knock out. 
Error bars indicate mean ± SD of two independent experiments (n=4). (B) Genotyping of the 
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We also noted that the LSK gating of the Cbfb-deleted mice showed the 
presence of a new population (C-kit intermediate / Sca-1 high), which was absent or 
at a very low level in the Cbfb-floxed controls (figure 4.2 A). Gating of these cells 
revealed that the majority of them were CD150-CD48+, a phenotype reminiscent of 


















Figure ‎4-2 Cbfb deleted mice had more HPC-1. 
(A) FACS profiles Show the LSK gating of the analysed mice, Floxed and KO. (B) FACS profile 
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 However, analysis at 8-weeks post tamoxifen administration showed no 
significant differences between the stem/progenitor cells of the tamoxifen treated 
mice and the Cbfb flox control mice (figure 4.3 A).  In contrast to PCR genotyping 
that confirmed a complete deletion 4 weeks after tamoxifen treatment, PCR 
genotyping 8 weeks post tamoxifen treatment revealed an incomplete Cbfb 
deletion (figure 4.3 B).  The reappearance of the floxed band suggests a strong 
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Figure ‎4-3 Four consecutive TAM injections were not enough to achieve a complete 
deletion of Cbfb. 
(A) Percentage of LSK and progenitors of the analysed mice 8 weeks after TAM treatment. 
Error bars indicate mean ± SD of two independent experiments (n=4).  (B) Genotyping of 
the experimental mice (one representative sample is shown). 
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To overcome this issue, we decided to repeat the experiments with a higher 
dose as well as the extended period of TAM treatment. The two groups of mice 
(Cbfbfl/fl Rosa 26 Cre ER and cbfbfl/fl) were treated with tamoxifen (120µl of 
10mg/ml) for five consecutive days. Surprisingly, the KO mice got sick within two 
weeks and they were culled together with the floxed control group and subjected 
to haematopoietic analysis. Our data showed that the KO mice had a significant 
reduction in white blood cells (WBC), red blood cells (RBC), platelets (PLT), and 
haemoglobin (HGB) concentration (figure 4.4 A-D). Moreover, flow-cytometric 
analysis of the BM cells using myeloid and lymphoid markers demonstrated that the 
KO mice had an increased percentage of Mac1 but a significant reduction in Gr1, 
B220 and CD8 cells comparing to the floxed group (figure 4.4 E). PCR genotyping 
confirmed a complete deletion of Cbfb (figure 4.4 F).  
HSCs analysis showed no significant difference in the term of the number of 
the LSK cells between the floxed and KO group. However, further analysis for this 
population showed significant reduction in HSC and MPP cells of the KO mice. In 
contrast, the KO mice had an increased percentage of HPC-2 comparing to the 
floxed one and a slight but not significant reduced percentage of the HPC-1 cells. 
With regards to the progenitors, the KO mice had a major reduction in CMP 
population but had relatively milder effect on the number of CLP, GMP and MEP 
(figure 4.4 G).   Overall, these results generated at 2 weeks and 4 weeks after a 
complete deletion of Cbfb in the whole animal consistently indicate an important 
function of Cbfb in normal haematopoietic development.  Next, we would like to 
examine if the effect was cell or non-cell autonomous.  
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Figure ‎4-4 Deleted cbfb mice had a sever defect in HSC and CMP. 
(A-D) Complete blood counts performed on flox and KO mice (n=4). (E) Percentage of 
myeloid and lymphoid cells in MB of flox and KO mice. (F) Genotyping of the analysed mice 
(representative samples). (G) Percentage of LSK and progenitors of the analysed mice. Error 
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4.2.2 Targeting Cbfb only in the haematopoietic cells resulted in HSCs and 
progenitors defects    
 
To complement the data obtained from Cbfb deletion in the whole animal, a 
transplantation assay was employed to delete Cbfb specifically in the 
haematopoietic cells of transplanted mice. To this end, mononuclear cells were 
isolated from two mouse models (Cbfbfl/fl Rosa 26 Cre ER and cbfbfl/fl).  One 
million cells of each genotype were separately injected into irradiated SJL (CD45.1) 
mice together with 0.2x106 rescue cells (figure 4.5). 4 weeks after transplantation, 
peripheral blood samples were taken and analysed for level of reconstitution, which 
would act as the basal line for subsequent comparisons. Mice were then subjected 
to tamoxifen treatment, in which Cbfb would only be deleted in the hematopoietic 
cells within the normal host environments. Then detailed HSC analyses were carried 
out at 4-, 8- and 12- weeks after tamoxifen treatment.  
While good and comparable reconstitutions were achieved using both 
Cbfbfl/fl Rosa 26 Cre ER and cbfbfl/fl cells, the percentage of CD45.2 donor cells in 
Cbfb KO mice was dramatically decreased compared with the flox control upon 
TAM treatment (figure 4.6 A and B). The FACS analysis of the PB showed no 
differences between the floxed and KO group before TAM treatments (figure 4.6 C). 
However, four weeks later the KO mice had reduced Mac1, Gr1, and CD4 positive 
cells with slightly higher percentage of Mac1Gr1 cells (figure 4.6 D). The FACS 
analysis at 8- and 12-weeks showed the KO mice had reduction only in Gr1, CD4 and 
CD8 positive cells comparing to the control group (figure 4.6 E and F). 
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Figure ‎4-6 Deletion of cbfb in the haematopoietic cells affect the distribution of myeloid 
and lymphoid cells in the peripheral blood. 
 (A and B) Percentage of blood reconstitution (CD45.2 in PB) before (A) and after (B) TAM 
treatments. (C-F) FACs analysis of PB cells before TAM treatment (C) and post treatment at 
4-, 8- and 12- weeks. Error bars indicate mean ± SD of two independent experiments (n=6 
mice for each group at each time point) 
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During the HSCs analysis, we observed a significant reduction in the number 
of CD45.2 BM mononuclear cells (MNCs) of the KO mice at 4-, 8- and 12-weeks post 
TAM treatments comparing to the floxed one (figure 4.7 A). In addition, FACS 
analysis of the BM cells showed KO mice had more Mac1 positive cells but with 
reduction in B220 positive cells (figure 4.7 B-D). These data were similar to what 
previously observed when Cbfb was ablated in the whole animal. Furthermore, the 
Gr1 positive cells of the KO mice started to reduce at 8-weeks post TAM treatment 
(figure 4.7 C and D).  Complete deletion of Cbfb was maintained throughout the 
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Figure ‎4-7 Deletion of cbfb in the haematopoietic cells affect the distribution of myeloid 
and lymphoid cells in the BM. 
 (A) CD45.2 BM MNCs cell count at 4-, 8- and 12-weeks post TAM treatment. (B-D) FACs 
analysis of BM cells at 4-, 8- and 12-weeks post TAM treatment. Error bars indicate mean ± 
SD of two independent experiments (n=6 mice for each group at each time point). (E) 
Genotyping of the analysed mice at 12-weeks (representative samples).  
 
To evaluate the impact of Cbfb deletion on the phenotypically defined stem 
and progenitor cells, FACS analysis were carried out at each time point to assess the 
percentage of these cells. We observed that LSK populations of the KO mice were 
gradually increased throughout the analysis in spite of a significant reduction of HSC 
and MPP at 8 and 12 weeks.  This was mainly due to the drastic expansion of HPC-2 
(Figure 4.8 A).  Consistent with the reduction of HSC and MPP, further analysis of 
the progenitor cells revealed significant reduction in CLP, CMP, GMP and MEP of 
the KO mice at 8-and 12-weeks comparing to the control group. To further examine 
the self-renewal property of Cbfb KO cells, they were transplanted into secondary 
recipients. As result, the KO cells were unable to reconstitute secondary recipient 
mice (figure 4.8 B).   
                  
WT         KO1       KO2        Flox1       Flox2         KO1     Flox1 






 Chapter 4 Cbfb in normal haematopoiesis 









Figure ‎4-8 Deletion of Cbfb only in the haematopoietic cells resulted in HSCs and 
progenitors defects. 
(A) Percentage of LSK and progenitors of the analysed mice at 4-, 8- and 12-weeks post 
TAM treatment. Error bars indicate mean ± SD of two independent experiments (n= 6 mice 
for each group at each time point). (F) Percentage of CD45.2 in PB of the secondary 
recipient mice at 4 weeks post transplantation (Error bars indicate mean ± SD of data 
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4.2.3 Targeting Cbfb only in the microenvironment doesn’t affect HSC and 
progenitor cells.   
 
 In the third approach, we decided to study the impact of Cbfb deletion in 
the microenvironments on development of haematopoietic stem and progenitor 
cells. To this end, two groups of CD45.2 mice (Cbfbfl/fl Rosa 26 Cre ER and cbfbfl/fl) 
were irradiated and transplanted with 1x106 MNC cells harvested from a WT mouse 
(CD45.1). After achieving good reconstitutions, the two groups were subjected to 
TAM treatment (IP: 5 consecutive days 120µL of 10mg/ml) to delete Cbfb in the 
environment and then a tail vein bleeding was carried out to study the impact of 
this deletion on normal haematopoiesis (figure 4.9).   
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We managed to achieve a good reconstitution after 4-weeks post 
transplantation with similar distribution of myeloid and lymphoid cell in the PB 
(figure 4.10 A and C). TAM treatment was then carried out for 5 consultative days. 
Surprisingly, deletion of Cbfb from the microenvironment had no effect on the 
percentage of reconstitution at 4-weeks post TAM treatment as compared to the 
control group (figure 4.10 B).  Moreover, myeloid and lymphoid FACS analysis of PB 
at 4-, 8- and 16- weeks post TAM treatment revealed no differences between the 
KO and floxed groups (figure 4.10 D-F).  However, the KO mice started to get sick at 
around 20-weeks post TAM treatment, therefore these mice were sacrificed 
together with the control one and subjected to HSCs analysis. To see if the deletion 
of Cbfb was maintained, ear biopsies were taken from the analysed mice and PCR 
genotyping was conducted. It was clear that completed deletion of Cbfb was 
maintained in the KO mice even after 20-weeks (figure 4.10 G).  On the other hand, 
as it was expected, genotyping of the BM cells showed only the WT band (figure 
4.10 H). Similar to the PB, FACS analysis of the BM cells showed no differences in 
the distribution of myeloid and lymphoid cells between the two groups (figure 4.10 
I). In addition, no significant difference was observed in the number of CD45.1 BM 
MNCs of the KO mice comparing to the flox one (figure 4.10 J). The phenotypic 
analysis of haematopoietic stem and progenitors cells revealed no significant 
differences between the two groups (figure 4.10 K). LSK populations of the KO mice 
were very similar to the floxed one with the exception of a slight expansion in HPC-
2 in some of the KO mice but it was not statistically significant (figure 4.10 K). HSC 
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of the KO mice was slightly reduced comparing to the flox one but it was also not 
statistically significant.  Finally, there were almost no differences observed in the 
progenitor populations between two groups (figure 4.10 K).  
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Figure ‎4-10 Deletion of Cbfb only in microenvironment had no effect on HSC and progenitor 
cells. 
 (A and B) Percentage of blood reconstitution (CD45.1 in PB) before (A) and after (B) TAM 
treatments. (C-F) FACs analysis of PB cells before TAM treatment (C) and post treatment at 
4-, 8- and 16- weeks. (G) Genotyping of ear biopsies of the analysed mice (representative 
samples). (H) Genotyping of BM cells of the analysed mice (representative samples). (I) 
FACs analysis of BM cells of the analysed mice. (J) CD45.1 BM MNCs cell count of the 
analysed KO and flox mice. (K) Percentage of LSK and progenitor cells of the analysed mice. 
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4.3 Discussion 
To gain insight into the role of Cbfb in normal adult haematopoiesis, in 
particular in HSC and progenitor development, I used SLAM markers and employed 
three different experimental settings to study the effects of loss of Cbfb on 
haematopoietic development in the whole animal, in haematopoietic cells or in the 
microenvirnoment only. Firstly, to delete Cbfb in the whole animal, Cbfbfl/fl Cre-ER 
mice as well as the control group (Cbfbfl/fl) were treated with tamoxifen (100µl of 
10mg/ml of 4-OHT) for four consecutive days. Analysis of their haematopoiesis was 
carried out at different time points (4-, 8-, and 12- weeks post treatment). In this 
experimental setting, deletion of Cbfb resulted in elevation of LSK populations with 
severe reduction in CMP. Interestingly, more refined gating within the LSK 
populations showed this elevation was due a specific increase of HPC-1 and HPC-2 
at the expense of HSC and MPP. On the other hand CLP, GMP and MEP progenitors 
were comparable to the control group. However, complete Cbfb deletion was not 
maintained for the 8- and 12- weeks as a result of strong selection for the Cbfb 
undeleted cells. Therefore, the time as well as the tamoxifen dose were increased 
(120µl of 10mg/ml of 4-OHT) for five consecutive days. Surprisingly, the KO mice 
started to get sick within 1-2 weeks post tamoxifen treatment, and were 
consequently sacrificed and subjected to HSCs analysis. These mice had low count 
for WBC, RBC, HGB and PLT counts with reduced B220 and CD8 cells but with high 
proportion of Mac1 expressing cells, similar to what have been reported recently by 
Wang and colleagues using Cbfbf/f Mx1-Cre mice despite the lack of achieving 
complete Cbfb deletion in their study (Wang, Chin et al. 2015). Contradictory to 
their study, HSCs and MPPs were significantly reduced in our mouse model whereas 
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the Cbfbf/f Mx1-Cre and Cbfbf/f Vav-iCre mice had more ST-HSC and MPP after 
Cbfb was targeted but not completely ablated. Using different Cre models (Mx1-Cre 
and Vav-iCre) and especially using different markers to phenotypically define the 
stem cells such as flt3, CD34 or SLAM markers (CD150 and CD48) might explain 
these differences. Nonetheless, my study together with their finding demonstrate 
that CMP cells required Cbfb for their maintenance as the three mice models 
showed drastic reduction in CMP after Cbfb deletion (Wang, Chin et al. 2015).  
Interestingly, deletion of Cbfb in the microenvironment resulted in no major effect 
on the normal haematopoiesis and the distribution and numbers of stem and 
progenitor cells were similar to controls. However, the KO mice started to be sick at 
around 20-weeks post tamoxifen treatment and the reason of this still not clear.          
To delineate the effect of Cbfb deletion in haematopoietic cells from non-
haematopoietic cells, I used a different experimental setting in which Cbfbfl/fl Rosa 
Cre ER cells (or Cbfbfl/fl as controls) were transplanted into WT recipient mice 
allowing specific deletion of Cbfb only in haematopoietic cells. Engraftment levels 
of greater than 60% were considered as a starting point of having “good seeds in 
good soil”. To study the effect of Cbfb deletion (only in haematopoietic cells) on 
HSC and progenitor development, the experimental mice were treated with 
tamoxifen and analysed at different time points (4-, 8- and 12- weeks). The data the 
percentage of CD45.2 transplanted cells in the peripheral blood was drastically 
reduced after Cbfb deletion and also the MNC numbers were reduced in the KO 
mice throughout the time of analysis (4-12 weeks). Moreover, we also observed a 
severe reduction of stem/progenitor cells especially HSCs and MPPs when Cbfb was 
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deleted similar to what was observed in the whole animal suggesting that the effect 
of Cbfb ablation on normal haematopoiesis might be in a cell-autonomous manner.  
It is interesting to note that our conditional mice still express the truncated 
Cbfb protein with defective Runx1 interaction ability, and it might rescue some of 
the haematopoietic defects especially when Cbfb was ablated in the whole animal. 
Indeed, ectopic expression of the Cbfb short form in Cbfb KO ES cells has been 
shown to rescue the definitive haematopoiesis defects (Miller, Stacy et al. 2001). 
Therefore the residual activity of this protein in the Cbfb KO embryos might explain 
the presence of having few definitive haematopoietic precursors (Wang, Stacy et al. 
1996; Miller, Stacy et al. 2001). 
To test the ability of Cbfb KO cells reconstituting secondary recipient, 
CD45.2 + cells (1x106) were sorted at 12-weeks post tamoxifen treatment and 
transplanted into secondary irradiated mice. The data demonstrated that the Cbfb 
KO cells failed to reconstitute secondary recipient mice comparing the WT cells 
suggesting a lack of HSC in the KO group. it has been demonstrated that Gata2 has a 
fundamental role for HSC generation and survival (de Pater, Kaimakis et al. 2013) 
and its expression was suppressed in the Cbfb KO cells (Wang, Chin et al. 2015). It is 
also possible that the homing properties of the Cbfb KO cells were severely 
compromised and which then failed to reconstitute secondary recipients. However 
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Over the past years, there has been a huge interest in developing protein-
protein interaction inhibitors that might hold the promise to eliminate cancers 
including haematological malignancies by disrupting alleged key protein 
interactions of the leukaemia initiating events. While in mixed lineage leukaemia 
inhibitors targeting the Menin-MLL interaction have been shown great promise in 
several models (Grembecka, He et al. 2012; Cao, Townsend et al. 2014; He, Senter 
et al. 2014), disrupting the interaction between AML1 and CBFB has  also been 
proposed as a promising way to treat CBF leukaemia and inhibitors are being 
developed (Gorczynski, Grembecka et al. 2007; Cunningham, Finckbeiner et al. 
2012). At the start of my PhD, the role of Cbfb in AE activity was not fully 
understood and the main aim was to use a Cbfb conditional knock out mouse 
model to clarify this by conducting in vitro experiments and also establishing an in 
vivo mouse model. My study clearly demonstrated that Cbfb is crucial for initiating 
of AE9a leukaemogenesis and also for the maintenance of this disease. However it 
was clear that different experimental strategies might lead to slightly different 
observations. For instance, AE9a in vitro activity was severely compromised in the 
fetal liver comparing to the adult BM cells. In addition, AE9a transformed LSK cells 
showed more Cbfb requirement comparing to CMP and GMP cells suggesting the 
cell of origin might have an impact and should be considered for the future studies. 
Although the in vitro data showed that Cbfb ablation had slightly higher effect on 
AE9a activity comparing to the full length (AE), future experiments are required to 
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further test the relevance of this observation.  One possible approach will be 
sorting of stem and progenitor cells from the BM and fetal liver cells of the Cbfb 
conditional KO mice and then transduce them either with AE9 or AE in the absence 
or presence of cooperative mutants such as NRAS. Then, the transduced cells 
should be subjected to direct injections in which the ablation of Cbfb will be carried 
out using tamoxifen. This approach will provide useful hints about the cell origin 
and requirement of Cbfb in AE9a leukaemogenesis versus the full length (AE), 
although the effect of cooperative mutations must be carefully evaluated.  
On the other hand, little was known about the role of Cbfb in adult 
haematopoiesis and I was able to show the importance of Cbfb in development of 
normal adult haematopoiesis during my PhD.  The data clearly demonstrated the 
crucial function of Cbfb in maintaining stem and progenitor haematopoietic cells in 
a cell-autonomous manner. Together, the results of this PhD revealed an important 
function of Cbfb in both normal and malignant haematopoiesis. Thus, treating AE 
leukaemia by direct inhibition of the interaction between AML1 and CBFB with 
small molecule inhibitors should be considered carefully. Further studies 
investigating the effect of these inhibitors on AE leukaemogenesis and normal 
haematopoiesis in parallel and also in details using relevant in vivo models should 
reveal the existence of potential therapeutic window that allow maximum effect AE 
leukemia with minimum effects on normal haematopoiesis. Additionally, the 
current AE9a leukaemia model should be used to generate RNA/ChIP-sequencing 
data that will help to shed light into the underlying mechanisms for the function of 
Cbfb which hopefully leads to the development of novel therapeutic targets for AE 
leukaemia that have no or minimum effect on normal haematopoiesis. 
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Appendix 
Table A1 (List1): Gene differentially downregulated in AE9a transformed cells with Cbfb flox 
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Table A2 List2: Gene differentially upregulated in AE9a transformed cells with Cbfb flox 
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Table A3: List of differentially expressed genes that were overlapped between Lo’s study 
and our study. List 3= AE9a dysregulated gene in Lo’s study vs our List 1. List 4= AE9a 
dysregulated gene in Lo’s study vs our list2.  










Crip1  hmgn3 


















Ndrg2  slco3a1 
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